document incorporate reference document annual report stockholder fiscal year part iiende december proxy statement annual meeting iii stockholder hold april table content item business item risk factor item unresolved staff comment item property item legal proceeding item submission matter vote security holder item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule signature computation ratio earning fix charge portion annual report stockholder subsidiary merck inc power attorney certify resolution board director certification certification certification certificationtable content item business merck inc merck company global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health directly joint ventures company sell product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution companys professional representative communicate effectiveness safety value product health care professional private practice group practice manage care organization overview december merck unveil plan reclaim leadership position pharmaceutical industry strategy merck focus improve research development productivity focus select therapeutic area implement new commercial model deliver great value customer reduce overall cost structure companywide merck new model design increase productivity improve probability success prioritize company resource priority disease area alzheimer disease atherosclerosis cardiovascular disease diabete novel vaccine obesity oncology pain sleep disorder therapeutic area carefully choose base set criterion include unmet medical need scientific opportunity commercial opportunity therapeutic area merck commit resource achieve research breadth depth develop bestinclass target differentiate product value highly patient payer physician company focus investment pursue specific mechanism follow select disease area antibiotic antifungal antiviral hepatitis virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize select opportunity outside area continue commercialize attractive clinical development candidate pipeline pursue appropriate external licensing opportunity merck latestage pipeline show strong progress biologic license application bla submission food drug administration fda new drug application nda file fda additional fda filing anticipate expect program phase iii quarter fda bla submission include gardasil breakthrough vaccine help prevent cervical cancer second leading cause cancer death women worldwide zostavax vaccine reduce incidence shingle rotateq pediatric vaccine prevent rotavirus gastroenteritis leading cause diarrhea infant young child lead nearly death worldwide year february merck announce approval fda rotateq addition february merck announce fda accept bla gardasil grant vaccine priority review designation fda review zostavax expected complete late february merck announce nda file fda januvia propose trademark compound know novel mechanism treatment type diabete accept standard review merck anticipate additional fda filing vorinostat generic suberoylanilide hydroxamic acid compound histone deacetylase inhibitor cancer intravenous prodrug aprepitant treat chemotherapyinduce nausea vomiting improve commercial selling model merck continue streamline restructure marketing sale operation worldwide improve effectiveness generate great efficiency united states company reduce number sale representative promote product percent versus historical level addition merck place emphasis active engagement key table content opinion leader accelerate development diffusion scientific information devote additional resource utilize technology demonstrate product value physician payer consumer increase influence prescription decision united states approach result considerable productivity improvement pilot program expect low company spend brand percent maximize sale performance provide additional support upcoming vaccine launch united states merck redeploy sale representative currently promote major inline product support launch new vaccine november company announce phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customerfocused manufacturing model year program merck plan sell close manufacture site preclinical site end eliminate approximately position companywide december approximately position company eliminate merck incur million cost associate global restructuring program comprise million separation cost million accelerate depreciation asset impairment cost manufacture facility include action ponder end united kingdom okazaki japan kirkland canada albany georgia danville pennsylvania preclinical site okazaki menuma japan company incur significantly large accelerate depreciation charge associate action asset impairment charge associate abandonment certain fix asset long business result restructuring action company plan close basic research center terling park united kingdom incur additional accelerate depreciation cost million respect site additional charge approximately million billion expect record base estimate time completion salesclosure facility previously discuss occur merck expect cost reduction program yield cumulative pre tax saving billion american job creation act ajca sign law october create temporary incentive december multinational repatriate accumulate income earn outside united states december connection ajca company repatriate billion result record income tax charge million charge partially offset million benefit associate decision implement certain tax planning strategy previously disclose september merck announce voluntary worldwide withdrawal vioxx arthritis acute pain medication result company record charge pretax income million million tax adjustment net income quarter include charge future legal defense cost vioxx withdrawal process complete cost associate withdrawal line original amount record company december company establish reserve million solely future vioxx legal defense cost company spend million aggregate vioxx legal defense cost worldwide fourth quarter company record charge million increase reserve solely future legal defense cost relate vioxx million december reserve base certain assumption good estimate company believe time reasonably estimate spend earning common share assume dilution include impact global restructuring program share net tax charge primarily associate ajca share additional reserve establish solely future legal defense cost vioxx litigation discuss table content product sale sale company product follow million zocor fosamax cozaarhyzaar singulair proscar primaxin vasotecvaseretic cosopttrusopt cancidas maxalt propecia vioxx vaccinesbiological total present net discount return company product include therapeutic preventive agent generally sell prescription treatment human disorder zocor simvastatin merck largestselle atherosclerosis product fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol merck osteoporosis product treatment case fosamax prevention osteoporosis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate company significant hypertensionheart failure product singulair montelukast sodium leukotriene receptor antagonist respiratory product treatment chronic asthma relief symptom allergic rhinitis proscar finasteride urology product treatment symptomatic benign prostate enlargement primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialanti fungal product cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselle ophthalmological product maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss vaccinesbiological include varivax varicella virus vaccine live okamerck live virus vaccine prevention chickenpox mmr measles mumps rubella virus vaccine live pediatric vaccine prevention measle mump rubella pneumovax pneumococcal vaccine polyvalent vaccine prevention pneumococcal disease recombivax hepatitis vaccine recombinant vaccine prevention hepatitis primarily include sale human pharmaceutical pharmaceutical animal health supply sale company joint venture revenue company relationship astrazeneca primarily relate sale nexium esomeprazole magnesium prilosec omeprazole product approval august company announce fda approve singulair symptom perennial allergic rhinitis yearround allergy adult child month age old september fda approve proquad measle mump rubella varicella okamerck virus vaccine live proquad combination vaccine simultaneous vaccination measle mump rubella varicella child month year age table content february merck announce approval fda rotateq pediatric vaccine prevent rotavirus gastroenteritis rotateq oral pentavalent threedose liquid vaccine contain human serotype merck submit application licensure rotateq country include australia canada countries asia latin america sanofi pasteur msd joint venture european union rotateq receive regulatory approval mexico november voluntary withdrawal vioxx september merck announce voluntary worldwide withdrawal vioxx arthritis acute pain medication company decision effective immediately base new threeyear datum prospective randomize placebocontrolle clinical trial approve adenomatous polyp prevention vioxx trial stop design evaluate efficacy vioxx prevent recurrence colorectal polyp patient history colorectal adenoma assess cardiovascular safety vioxx study increase relative risk confirm cardiovascular event heart attack stroke begin month treatment patient take vioxx compare take placebo result month approve study increase risk confirm cardiovascular event vioxx respect similar result placebocontrolle study describe recent labeling vioxx company estimate million prescription write vioxx august base estimate company estimate number patient take vioxx united states launch approximately million number patient outside united states take vioxx undetermined time october company receive letter senator charles grassley chairman senate committee finance request certain document information relate vioxx company receive request information congressional committee company intend cooperate inquiry company continue describe reason company voluntary withdrawal vioxx answer question relate company development extensive testing medicine disclosure result study february fda hold joint meeting arthritis advisory committee drug safety risk management advisory committee committee discuss overall benefittorisk consideration include cardiovascular gastrointestinal safety concern cox selective nonsteroidal antiinflammatory drug relate agent february member committee ask vote overall risk versus benefit profile vioxx support marketing united states member committee vote support marketing vioxx united states company look forward discussion fda regulatory authority vioxx previously announce board director company appoint special committee review company action prior voluntary withdrawal vioxx act board respond shareholder litigation matter relate withdrawal vioxx advise board respect action take result review review ongoing arcoxia arcoxia launch country europe latin america asia africa october company receive approvable letter fda company nda arcoxia fda inform company letter approval nda issue additional safety efficacy data arcoxia require november european commission adopt binding decision cox inhibitor product include arcoxia market decision result review committee medicinal product human use chmp table content european medicine evaluation authority emea consider aspect cardiovascular safety cox inhibitor include thrombotic cardiorenal event follow voluntary withdrawal vioxx decision adopt opinion emea issue june recommend new cardiovascular contraindication warning inclusion label cox inhibitor include arcoxia chmp conclude available datum increase risk cardiovascular adverse event cox inhibitor class relative placebo nsaids data suggest association duration use dose probability suffer cardiovascular event label modification include emeas opinion reflect use low effective dose cox inhibitor shortest possible duration treatment recommend contraindication cox inhibitor patient ischemic heart disease stroke contraindication certain patient high class congestive heart failure include specifically respect arcoxia label change include contraindication patient hypertension blood pressure control arcoxia associate frequent severe effect blood pressure particularly high dose cox inhibitor recommend monitor blood pressure patient take arcoxia additional warning hypersensitivity skin reaction include label cox inhibitor regulatory agency country arcoxia approve modification product label arcoxia cox inhibitor relative cardiovascular risk patient usage september venezuelan ministry health order market withdrawal cox inhibitor include arcoxia mexico sales arcoxia temporarily suspend suspension lift acquisition cid march company acquire aton pharma inc aton privately hold biotechnology company focus development novel treatment cancer disease aton clinical pipeline histone deacetylase inhibitor represent class antitumor agents potential efficacy base novel mechanism action lead product candidate suberoylanilide hydroxamic acid know vorinostat currently phase clinical trial treatment cutaneous tcell lymphoma company wholly own subsidiary msd japan ltd complete tender offer acquire remain common share banyu pharmaceutical ltd banyu aggregate purchase price approximately billion march merck complete acquisition banyu ownership banyu strengthen merck position japan world secondlarg pharmaceutical market joint venture cid company scheringplough corporation scheringplough enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december cholesterolmanagement partnership agreement expand include country world exclude japan october zetia ezetimibe market ezetrol outside united states new class cholesterollowere agent launch united states july vytorin ezetimibesimvastatin market inegy outside united states combination product contain active ingredient zetia zocor approve united states november merckscheringplough partnership announce commencement patient enrollment largescale clinical outcome trial improveit improve reduction outcome vytorin efficacy international trial trial evaluate effectiveness vytorin compare zocor treat approximately high risk patient coronary artery disease present acute coronary syndrome clinical trial site open north america europe company enter agreement astra astra develop market astra product united states company astra form equally own joint venture develop market astra new prescription medicine united states include prilosec table content class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership company maintain limited partner interest partnership rename astrazeneca exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership gaap earning conjunction restructure payment million astra purchase option buy company interest kbi product exclude company interest gastrointestinal medicine nexium prilosec company grant astra option share option buy company common stock interest kbi exercise price base present value estimate future net sale nexium prilosec april astra merged zeneca group plc form astrazeneca astrazeneca result merger exchange company relinquishment right future astra product exist pende patent time merger astra pay million subject trueup calculation require repayment portion merger trigger partial redemption company limited partner interest furthermore result merger astrazenecas option buy company interest kbi product exercisable company right require astrazeneca purchase interest addition share option exercisable year astra purchase company interest kbi product exercise option astra provide year combine annual sale product fall minimum provide case long merck option astrazenecas option exercise exercise price base present value estimate future net sale nexium prilosec determine time exercise company form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture expand europe canada significant joint venture product pepcid famotidine overthecounter form company ulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide march company sell johnson johnson interest european joint venture discuss divestiture effective april company merck vaccine division connaught laboratories inc sanofi pasteur agree collaborate development marketing combination pediatric vaccine promote select vaccine united states research marketing collaboration enable company pool resource expedite development vaccine combine different antigen protect child variety disease include haemophilus influenzae type hepatitis diphtheria tetanus pertussis poliomyelitis combination vaccine development effort continue agreement vaccine currently promote company merck vaccine division pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution exist european free trade association company sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture subject monitor partner certain undertaking return exemption european competition law effective december joint venture maintain presence directly table content affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory september sanofi pasteur msd spmsd mercks vaccine joint venture sanofi pasteur enter letter undertake lou emea emeas concern longterm efficacy hepatitis component hexavac hepatitis component hexavac manufacture merck lou require relevant suspension hexavac license suspension hexavac distribution recall hexavac product recall hexavac number noneu country surveillance program possible future revaccination spmsd market sell hexavac notify merck reserve right seek damage merck defend indemnify hold harmless merck event party claim september emea initiate formal review longterm efficacy hepatitis vaccine hbvaxpro hepatitis component hepatitis bhib combination vaccine procomvax product market sell spmsd european territory sell different name merck assessment report prepare chmp merck response consider chmp meeting february expect chmp conclude review april company rhnepoulenc sanofiaventis combine respective animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie merial divest entire poultry genetic business segment domestic turkey layer segment divest respectively broiler foreign turkey segment sell competition cid market company pharmaceutical business conduct highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access competition involve intensive search technological innovation ability market innovation effectively longstanding emphasis research development company prepare compete search technological innovation additional resource meet competition include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product joint venture license refine sale marketing effort address change industry condition enhance product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition introduction new product process competitor result price reduction product replacement product protect patent example number compound available treat disease typically increase time result slow growth sale certain company product legislation enact states united states particularly area human pharmaceutical product allow encourages instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator product brandname product governmental pressure dispense generic product significantly reduce sale certain company product long protect patent vasotec vaseretic enalapril maleate combination hydrochlorothiazide right sell addition zocor lose patent protection certain country outside united states company experience decline zocor sale country table content distribution cid company sell human health product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution vaccine sell directly physician company professional representative communicate effectiveness safety value company product health care professional private practice group practice manage care organization fourth quarter company implement new distribution program wholesaler moderate fluctuation sale cause wholesaler investment buying improve efficiency distribution company pharmaceutical product new program lower previous limit average monthly purchase company pharmaceutical product customer follow implementation program fluctuation sale cause wholesaler investment buy significantly moderate raw material cid raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business government regulation investigation cid pharmaceutical industry subject global regulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states food drug administration modernization act fda modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government expand health care access enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january new benefit support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time benefit ensure prescription drug cost control competitive pressure encourage appropriate use medicine address costcontainment pressure company continue effort demonstrate medicine help save cost overall patient health care year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary variously review company believe continue able conduct operation include introduction new drug market regulatory environment type federal initiative contain federal health care spending prospective capitate payment system implement reduce rate growth medicare reimbursement hospital system establish advance flat rate reimbursement health care patient payor fiscally responsible type payment system cost containment system widely public private payor cause hospital health maintenance organization customer company cost conscious treatment decision include decision medicine available patient company continue work private federal employer slow increase health care cost company effort demonstrate medicine help save cost area table content encourage use company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child company award cdc contract supply million pediatric vaccine vaccine children program january patient previously eligible medicaid medicare beneficiary year old disabled leave stateadministere medicaid system cover new medicare prescription drug benefit outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price prescription drug profit prescription drug company adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment addition certain country recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation increase focus privacy issue country world include united states united states government pursue legislative regulatory initiative privacy include federal privacy regulation recently enact state privacy law concern health personal information affect company operation patent trademark license cid patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance date grant legal life patent country protection afford vary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclusivity basic patent effect follow major product united states cancidas comvax haemophilus conjugate hepatitis recombinant vaccine cosopt cozaar crixivan emend aprepitant fosamax hyzaar invanz ertapenem sodium maxalt primaxin propecia finasteride proscar recombivax table content singulair timopticxe timolol maleate ophthalmic gel form solution trusopt zocor basic patent effect united states zetia vytorin develop merckscheringplough partnership basic patent effect sustivastocrin efavirenz bristolmyers squibb bms exclusive license company sell sustiva united states canada certain european country company market stocrin country world basic patent aggrastat tirofiban hydrochloride united states divest product company retain basic patent aggrastat outside united states fda modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize october good pharmaceuticals child act pass january fda grant additional month market exclusivity united states invanz august fda grant additional month market exclusivity united states trusopt october fda grant additional month market exclusivity united states cozaarhyzaar february fda grant additional month market exclusivity united states singulair august information respect company patent patent litigation expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states market exclusivity available federal law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty june zocor lose market exclusivity united states company expect significant decline zocor sale time june basic patent united states cover proscar expire result company expect significant decline proscar sale time basic patent proscar cover propecia propecia protect additional patent expire october fda grant additional month market exclusivity united states fosamax february fosamax weekly january january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax lose market exclusivity united states february company expect significant decline fosamax sale time worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely table content royalty receive patent knowhow license right amount million company pay royalty amount million patent knowhow license hold discontinued operation cid august company complete spinoff medco health solutions inc medco health separate publiclytrade company spinoff effect way pro rata dividend company stockholder outstanding share common stock medco health base letter rule company receive internal revenue service receipt medco health share distribution taxfree federal income tax purpose cash receive lieu fractional share taxable divestiture cid march company complete sale johnson johnson companys equity stake european nonprescription pharmaceutical joint venture johnson johnson company sell right aggrastat guilford pharmaceuticals inc include basic product patent process patent product company sell right vasotec vaseretic vasotec injection enalaprilat biovail laboratory incorporate biovail subsidiary biovail corporation time company canadian subsidiary merck frosst canada merck frosst biovail enter supply agreement merck frosst agree supply biovail minimum year bulk tablet formulate enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patent vasotec vaseretic expire united states prior transaction research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity expenditure company research development program billion billion billion estimate continue level fullyear expense company maintain ongoing commitment research broad range therapeutic area clinical development support new product total expenditure period exceed billion compound annual growth rate company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development merck new model design increase productivity improve probability success prioritize company resource priority disease area alzheimer disease atherosclerosis cardiovascular disease diabete novel vaccine obesity oncology pain sleep disorder therapeutic area carefully choose base set criterion include unmet medical need scientific opportunity commercial opportunity therapeutic area merck commit resource achieve research breadth depth develop bestinclass target differentiate product value highly patient payer physician company focus investment pursue specific mechanism follow select disease area antibiotic antifungal antiviral hepatitis virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize select opportunity outside area continue commercialize attractive clinical development candidate pipeline pursue appropriate external licensing opportunity development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug market table content united states record datum preclinical clinical experience include nda bla fda require approval development certain product subject government regulation cover safety efficacy united states foreign country company scientist discover new compound believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness result phase trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market united states fda approval process begin complete nda submit receive fda pursuant prescription drug user fee act fda review period target nda supplemental nda month priority review month standard review day receipt nda fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review review timeline define fda act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information day extension review period communicate company base fda statistics drug development time initiation preclinical testing nda approval range year average year june fda accept standard review bla zostavax mercks investigational vaccine prevention herpe zoster commonly know shingle adult year age old sanofi pasteur msd submit application licensure zostavax merck submit application licensure zostavax australia canada countries asia latin america february fda extended review zostavax month late september merck present study phase datum company dpp inhibitor januvia propose trademark sitagliptin potential new approach treatment type diabete annual meeting european association study diabete february merck announce nda januvia accept standard review fda merck expect fda action nda midoctober december merck submit bla fda gardasil quadrivalent human papillomavirus type recombinant vaccine company vaccine protect type human papillomavirus hpv type account estimate cervical cancer case type account estimate genital wart case february merck announce fda accept bla gardasil investigational cervical cancer vaccine give priority review agency priority designation intend product address unmet medical need prescription drug user fee act blas file fda goal review act blas designate priority review month receipt fda informed merck review goal date june submission fda december merck submit application gardasil table content additional regulatory agency include australia mexico brazil argentina taiwan singapore companys earlystage clinical pipeline include candidate follow area arthritis atherosclerosis cancer cardiovascular disease diabete endocrine disorder glaucoma infectious disease insomnia neurodegenerative disease obesity osteoporosis psychiatric disease pain respiratory disease urogenital disorder vaccine company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company complete transaction include research collaboration preclinical clinical compound technology transaction broad range therapeutic category include neuroscience obesity oncology merck bioxell enter agreement develop new treatment sepsis inflammatory disorder june vical incorporate vical exercise option amendment exist research collaboration licensing agreement grant merck right use vical patent nonviral gene delivery technology cancer vaccine application merck vertex pharmaceutical incorporate announce june initiation additional phase clinical study small molecule inhibitor aurora kinases aurora kinase implicate onset progression human leukemia dainippon sumitomo pharma ltd know sumitomo pharmaceutical ltd sumitomo merck sign agreement june collaborate lurasidone atypical antipsychotic compound currently phase development treatment schizophrenia chronic disable severe mental illness agreement sumitomo grant merck affiliate exclusive license part world japan china korea taiwan june merck announce agreement metabasis therapeutic research develop commercialize novel small molecule therapeutic potential treat disease include type diabetes hyperlipidemia obesity activation enzyme liver call ampactivated protein kinase july merck geron corporation announce agreement develop cancer vaccine telomerase telomerase enzyme active cancer cell maintain telomere length end chromosome activity allow cancer grow metastasize long period time september foxhollow technologies inc merck announce formation novel pharmacogenomic collaboration collaboration focus analyze atherosclerotic plaque remove patient artery mean identify new biomarker atherosclerotic disease progression use development cardiovascular compound merck pipeline agreement include research collaboration year october agensys inc agensys cancer biotechnology company merck announce form global alliance jointly develop commercialize agspsca agensys fully human monoclonal antibody prostate stem cell antigen psca agreement grant merck worldwide right agspsca exclusive license psca proprietary target right therapeutic diagnostic product develop alliance october merck bms jointly announce sign separate license agreement international partnership microbicide develop new antiretroviral compound potential microbicide protect woman hiv compound new class anti table content retroviral know entry inhibitor compound bind directly hiv bind ccr receptor design prevent hiv efficiently enter host cell prevent infection company bm report october fda issue approvable letter pargluva bmss investigational oral medicine treatment type diabetes fda request additional safety information ongoing trial complete safety datum formal regulatory submission address fully cardiovascular safety profile pargluva datum requirement cause significant delay product launch result bms company terminate collaborative agreement pargluva right pargluva compound pargluva return bms december chart reflect company current research pipeline february candidate show phase iii include specific product candidate show phase include advanced compound specific mechanism give therapeutic area compound regardless phase development additional indication therapeutic area additional line extension formulation inline product show company program generally design focus development novel medicine address large unmet medical need phase phase phase phase iii review alzheimer disease diabete arthritis aid hpv relate cervical cancer cancer ctcl atherosclerosis genital wart arthritis vorinostat mkb gardasil endocrine endocrine mka atherosclerosis cinv shingles flu vaccine hiv vaccine zostavax glaucoma hpv vaccine diabete hypertension mka diabete cancer insomnia insomnia januvia obesity gaboxadol obesity approvable agensys nastech pyy arthritispain osteoporosis osteoporosis arcoxia pain pain approval cancer vaccine neurogen osteoporosis cardiovascular parkinson disease fosamax plus pediatric vaccine psychiatric disease pediatric vaccine proquad psychiatric disease respiratory disease approval lurasidone rotavirus aureus vaccine stroke gastroenteritis ono rotateq urinary incontinence licensed alliance acquisition pipeline multiple license include csl ltd merck discussion license partner plan compound march merck terminate agreement nastech pharmaceutical company inc respect pyy product service mark appear type form different surround text trademark service mark own license merck subsidiary affiliate include zetia vytorin trademark own entity merckscheringplough partnership note cozaar hyzaar register trademark pont nemours company wilmington prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own table content biovail laboratory incorporate trademark aggrastat own guilford pharmaceuticals inc trademark pargluva own bms employee end company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group costreduction initiative announce october complete end company eliminate position company complete similar program position eliminate december november company announce phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customerfocused manufacturing model year result merck incur certain cost associate exit disposal activity global restructure program company expect eliminate approximately position manufacture division worldwide represent global work force end half position reduction expect occur united states remainder country merck intend sell close manufacture facility worldwide reduce operation number site company expect close basic research site preclinical development site site identify closure expect closed end subject compliance legal obligation pretax cost restructure million expect million billion end initial phase restructuring program substantially complete cumulative pretax cost restructuring activity announce november expect range billion billion approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility schedule closure environmental matter company believe compliance material respect applicable environmental law regulation company incur capital expenditure approximately million environmental protection facility company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million year amount consider potential recovery insurer party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess provide result material adverse effect company financial position result operation liquidity capital resources geographic area segment information company operation principally manage product basis reportable segment merck pharmaceutical segment include product market directly joint venture merck pharmaceutical product consist therapeutic preventive agent sell prescription treatment prevention human disorder table content company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition recent year company expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible company earn fair return business develop area stable offer important opportunity growth time financial information geographic area operate segment company business incorporate reference page begin caption segment reporting company annual report stockholder available information company internet website address wwwmerckcom company available free charge investor information portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director seven stand committee available company website wwwmerckcomaboutcorporategovernance information available print stockholder request company item risk factor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forward look statement involve risk uncertainty company result materially differ anticipate forward look statement result certain factor include risk face describe cautionary factor affect future result company face significant litigation relate vioxx september company voluntarily withdraw vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuit involve approximately plaintiff group allege personal injury result use vioxx file company state federal court united states company defendant purport class action relate use vioxx suit refer vioxx product liability lawsuit addition vioxx product liability lawsuit number purport class action bring company current officer director company allege company false misleading statement vioxx violation federal security law suit refer vioxx security lawsuit employee retirement income security act erisa suit refer vioxx erisa lawsuit addition number shareholder file derivative suit shareholder table content file demand assert claim board member company officer suit refer vioxx derivative lawsuit vioxx security lawsuit vioxx erisa lawsuit vioxx shareholder lawsuit company name defendant action country outside united states suit refer vioxx foreign lawsuit company sue state respect marketing vioxx company anticipate additional lawsuit relate vioxx file andor certain current officer director future sec conduct formal investigation company concern vioxx department justice issue subpoena request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute ongoe investigation certain congressional committee local authority europe group attorney general thirtyone state district columbia conduct investigation company sale marketing vioxx company cooperate authority investigation investigation refer vioxx investigation company predict outcome investigation result potential civil andor criminal liability vioxx product liability lawsuit go trial result jury verdict august trial state court texas jury ernst merck reach verdict favor plaintiff purport award total million compensatory punitive damage texas law maximum award plaintiff cap approximately million company intend appeal verdict completion posttrial proceeding trial court believe strong point raise appeal company believe potential unfavorable outcome probable company establish reserve respect verdict november second vioxx personal injury case trial frederick mary jackson humeston merck inc superior court new jersey law division atlantic county jury return verdict favor company count jury find vote company fail provide adequate warning prescribing physicians association vioxx increase risk cardiovascular event prior humeston heart attack jury unanimously find company violate new jersey consumer fraud act marketing drug prescribing physicians february retrial case federal court new orleans bring evelyn irvin plunkett behalf late husband richard irvin die apparent heart attack jury return verdict favor merck count outcome vioxx product liability trial interpret indicate trend outcome likely future vioxx trial company currently anticipate number vioxx product liability lawsuit try company predict timing trial respect vioxx shareholder lawsuit company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company believe insurance coverage respect vioxx lawsuit adequate cover defensive cost loss company spend million aggregate legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation fourth quarter company record charge million increase reserve solely future legal defense cost relate vioxx litigation million december million december reserve base certain assumption describe legal proceeding good estimate table content company believe time reasonably estimate spend company currently able estimate damage require pay connection vioxx lawsuit vioxx investigation proceeding expect continue year currently early stage company little information course view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit company establish reserve potential liability relate vioxx lawsuit vioxx investigation series unfavorable outcome vioxx lawsuit vioxx investigation result payment substantial damage fine result criminal penalty material adverse effect company business cash flow result operation financial position prospect certain company major product go lose patent protection near future occur company expect significant decline sale product company depend patent provide exclusive marketing right product period time product patent company product recently expire expire united states country company face strong competition low price generic drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company result operation zocor company statin modifying cholesterol currently large revenueproduce product lose basic patent protection canada certain country europe include united kingdom germany company experience decline zocor sale country result availability generic version worldwide sale zocor billion compare billion june zocor lose market exclusivity united states company expect significant decline zocor sale time august opposition division european patent office render decision revoke company patent europe cover weekly administration alendronate decision appeal hear schedule march decision proceeding typically render end hearing decision upheld company entitle market exclusivity fosamax major european market merck basic patent covering use alendronate challenge european country company unsuccessful country company lose exclusivity right fosamax country company expect significant decline european sale fosamax loss exclusivity sale fosamax outside united states adversely affect availability generic product market include united kingdom canada germany nonetheless global sale fosamax grow billion result strong sale united states january court appeal federal circuit washington find company patent claim weekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax lose market exclusivity united states february company expect significant decline fosamax sale time table content company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year decline sale product zocor fosamax mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party support research development effort company ongoing substantial expenditure assurance effort funding result commercially successful product company commit substantial effort fund resource recruit retain high quality scientist personnel pharmaceutical research development expertise base fda statistics drug development time initiation preclinical testing nda approval range year average year description research development process research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal accordingly company abandon product invest substantial amount time money risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug sale new product disappointing company state certainty product development launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product zocor fosamax lose patent protection displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include european commission united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawal company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant table content delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party legal proceeding patent litigation particular manufacturer generic pharmaceutical product time time file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case party patent prevent company marketing selling product particular geographic area important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company successfully launch commercially successful replacement product company face intense competition lowercost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation encourages use generic product company policy actively protect patent right generic challenge company product arise time able prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially result operation cash flow company face intense competition new product company product face intense competition competitor product competition increase new product enter market event competitor product safe table content effective effectively market sell company product alternatively case generic competition equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business result operation cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company caution place undue reliance forwardlooke statement possible predict identify factor include follow significant litigation relate vioxx competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation enforcement thereof affect company business table content efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states united states federal state government pursue legislative regulatory initiative patient privacy include federal recently issue state privacy regulation concern health information affect company operation change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarters locate whitehouse station new jersey company pharmaceutical business conduct divisional headquarters locate upper gwynedd west point pennsylvania company vaccine business conduct divisional headquarters locate west point principal research facility human health product locate rahway new jersey west point company production facility human health product location united states puerto rico branch warehouse provide service country outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion compare billion united states amount million billion abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need table content exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action vioxx litigation product liability lawsuit previously disclose federal state product liability lawsuit involve individual claim putative class action file company respect vioxx december company serve aware name defendant approximately lawsuit include approximately plaintiff group allege personal injury result use vioxx lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl discuss approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol higbee certain lawsuit include allegation gastrointestinal bleed cardiovascular event thrombotic event kidney damage company name defendant approximately putative class action allege personal injury seek medical monitoring result putative class member use vioxx disgorgement certain profit common law unjust enrichment theory andor iii remedy state consumer fraud fair business practice statute include recover cost vioxx purchase individual thirdparty payor union health plan action discuss paragraph collectively refer vioxx product liability lawsuit action file state court california texas new jersey philadelphia pennsylvania respectively transfer single judge state coordinate proceeding february judicial panel multidistrict litigation jpml transfer vioxx product liability lawsuit pende federal court nationwide multidistrict litigation mdl coordinated pretrial proceeding mdl transfer united states district court eastern district louisiana district judge eldon fallon judge fallon indicate intends try series case period november follow category heart attack short term use heart attack long term use iii stroke cardiovascular injury involve prescription write april labeling vioxx revise include result vigor trial november december case bring evelyn irvin plunkett behalf late husband richard irvin die apparent heart attack try houston texas plaintiff allege irvin take vioxx approximately month action fall category heart attack short term use deliberate onehalf day court find jury deadlocke declare mistrial federal court rule require unanimous verdict retrial case commence february new orleans louisiana february jury return verdict favor merck count schedule mdl trial diaz merck case plaintiff claim heart attack long term use schedule june previously schedule addition diaz case garza case discuss vioxx product liability lawsuit currently schedule trial company intend provide list trial website wwwmerckcom periodically update appropriate company include website address inactive textual reference intend active link website incorporate reference information contain table content merck enter tolling agreement tolling agreement mdl plaintiff steering committee establish procedure halt run statute limitation toll certain category claim allegedly arise use vioxx nonnew jersey citizens tolling agreement apply individual file lawsuit eventually file lawsuit claimant seek toll claim allege injury result thrombotic cardiovascular event result myocardial infarction ischemic stroke tolling agreement provide counsel additional time evaluate potential claim tolling agreement require toll claim file federal court december approximately claimants enter tolling agreement previously disclose august trial state court texas jury ernst merck reach verdict favor plaintiff purport award total million compensatory punitive damage texas law maximum award plaintiff cap approximately million company intend appeal verdict completion posttrial proceeding trial court company believe strong point raise appeal hopeful appeal process correct verdict company believe potential unfavorable outcome probable establish reserve respect verdict november case frederick mary jackson humeston merck superior court new jersey law division atlantic county jury return verdict favor merck counts case second vioxx personal injury case trial humeston year old united states postal employee idaho allege suffer heart attack september result take vioxx seek compensatory punitive damage jury find vote merck fail provide adequate warning prescribing physicians association vioxx increase risk cardiovascular event prior humeston heart attack jury unanimously find merck violate new jersey consumer fraud act marketing drug prescribing physician trial garza heart clinic evans posada merck begin january judicial district court starr county texas company believe evidence case vioxx cause heart attack leonel garza garza die heart attack april follow year cardiovascular disease prior heart attack approximately month death company maintain garza give oneweek supply vioxx sample pain addition trial proceeding consolidate trial cona merck mcdarby merck begin february new jersey superior court law division atlantic county judge higbee company believe evidence vioxx cause mcdarby cona heart attack lawsuit previously disclose july new jersey state trial court certify nationwide class thirdparty payor union health insurance plan pay vioxx plan member insureds name plaintiff case seek recovery certain vioxx purchase cost plus penalty base allegation purport class member pay vioxx know product allege risk merck believe class improperly certify trial court rule procedural address merit plaintiff allegation company intend defend vigorously new jersey state superior court appellate division accept merck appeal class certification order expedite basis previously report company name defendant separate lawsuit bring attorney general louisiana mississippi texas attorney general alaska recently file lawsuit action allege company misrepresent safety vioxx seek recovery cost vioxx purchase reimburse state agency reimbursement sum pay state agency medical service treatment person injure vioxx iii damage common law theory andor remedy state statutory theory include state table content consumer fraud andor fair business practice medicaid fraud statute include civil penalty shareholder lawsuit previously disclose addition vioxx product liability lawsuit company current officer director company defendant number putative class action individual lawsuit file removed federal court shareholder federal security law vioxx security lawsuit transfer jpml relate lawsuit discuss united states district court district new jersey district judge stanley chesler inclusion nationwide mdl coordinated pretrial proceeding shareholder mdl judge chesler consolidated vioxx security lawsuit purpose june plaintiffs vioxx security lawsuit file fourth consolidated amend class action complaint supersede prior complaint case complaint plaintiff request certification class purchaser company stock october complaint allege defendant false misleading statement vioxx violation section securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale merck stock addition complaint include allegation section security act certain defendant incomplete misleading statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan defendant file motion dismiss complaint pende previously disclose august complaint file oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current officer director complaint bring oregon security law allege plaintiff suffer damage connection purchase merck common stock artificially inflate price company allege violation law relate disclosure vioxx company remove lawsuit district court district oregon plaintiff move remand case state court motion grant previously disclose number shareholder derivative action file federal court new jersey superior court naming company nominal defendant certain member board past present certain executive officer defendant complaint arise substantially factual allegation vioxx security lawsuit derivative suit purportedly bring assert right company assert claim board member officer breach fiduciary duty waste corporate asset unjust enrichment abuse control gross mismanagement action discuss paragraph collectively refer vioxx derivative lawsuit jpml transfer vioxx derivative lawsuit pende federal court shareholder mdl judge chesler consolidated vioxx derivative lawsuit purpose june federal derivative plaintiff file verify consolidated shareholder derivative complaint supersede prior complaint case defendant file motion dismiss complaint pende addition vioxx derivative lawsuit pende new jersey superior court consolidate transfer judge higbee atlantic county april state plaintiff file supersede verify consolidate amend shareholder derivative complaint january shareholder derivative case dismiss prejudice case dismiss court grant defendant motion stay case court order permit plaintiff refile complaint consolidated federal shareholder derivative case resolve previously disclose october individual shareholder demand board legal action raymond gilmartin chairman president chief executive officer individual allegedly cause damage company respect allegedly improper marketing vioxx response demand letter board director determine november meeting board shareholder request consideration remain consideration table content addition previously disclose number putative class action file company certain current officer director company federal court vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit behalf certain company current employee participant certain company retirement plan assert claim employee retirement income security act erisa lawsuit similar allegation allegation contain vioxx security lawsuit claim defendant breach duty plan fiduciarie jpml transfer vioxx erisa lawsuit shareholder mdl judge chesler consolidated vioxx erisa lawsuit purpose consolidate amend complaint file vioxx erisa lawsuit august defendant file motion dismiss complaint pende international lawsuit previously disclose addition lawsuit discuss company name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil australia turkey israel additional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future insurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible coinsurance insurance provide coverage legal defense cost potential damage amount incur connection vioxx product liability lawsuit company believe insurance coverage extend additional vioxx product liability lawsuit file future company director officers insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million additional insurance coverage claim available upperlevel excess policy provide coverage variety risk dispute certain insurer availability insurance coverage likely additional dispute time company believe insurance coverage respect vioxx lawsuit adequate cover defense cost loss previously disclose company upper level excess insurer provide excess insurance potentially applicable vioxx lawsuit commence arbitration seek thing cancel policy void obligation policy raise coverage issue respect vioxx lawsuit second arbitration company upper level excess insurer commence merck intend contest vigorously insurer claim attempt enforce right applicable insurance policy amount actually recover policy discuss section amount specify precede paragraph investigation previously disclose november company advise staff sec commence informal inquiry concern vioxx january company announce receive notice sec issue formal notice investigation company receive subpoena department justice doj request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute ongoe investigation certain congressional committee previously disclose company subsidiary notify medicine healthcare table content product regulatory agency united kingdom mhra investigation mhra compliance company adverse experience reporting requirement connection vioxx addition previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company receive civil investigative demand cid group attorney general state district columbia investigate company violate state consumer protection law marketing vioxx company cooperate attorney general respond cid reserve company currently anticipate number vioxx product liability lawsuit try company predict timing trial respect vioxx shareholder lawsuit company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit company establish reserve potential liability relate vioxx lawsuit vioxx investigation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company establish reserve million solely future legal defense cost relate vioxx litigation company spend million aggregate legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation fourth quarter company record charge million increase reserve solely future legal defense cost relate vioxx litigation million december reserve base certain assumption good estimate company believe time reasonably estimate spend significant factor consider establishment ongoing review reserve vioxx legal defense cost follow actual cost incur company time development company legal defense strategy structure light scope vioxx litigation number case bring company cost outcome complete trial anticipate timing progression relate cost pretrial activity trial vioxx product liability lawsuit event schedule trial expect occur inherent inability predict ultimate outcome trial limit company ability reasonably estimate legal cost end company continue monitor legal defense cost review adequacy associate reserve unfavorable outcome vioxx itigation material adverse effect company financial position liquidity result operation commercial litigation begin company name number antitrust suit certain certify class action institute nation retail pharmacy consumer state company settle federal class action represent single large group claim settle substantially remain case satisfactory term remain case inactive year company engage conspiracy admission wrongdoing include settlement agreement previously disclose company join ongoing litigation allege manipulation table content pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company pharmaceutical manufacturer defendant similar complaint pende federal state court bring individually number county state new york company defendant await final rule motion dismiss suffolk county case new york county case file addition december company defendant state case bring attorney general kentucky illinois alabama wisconsin mississippi arizona vigorously defend company receive letter inquiry attorney general idaho previously disclose company name defendant antitrust case federal court minnesota state court california allege unlawful conspiracy different set pharmaceutical manufacturer protect high price united states impede importation united states lowerpriced pharmaceuticals canada court dismiss federal claim minnesota case prejudice plaintiff file notice appeal state claim action dismiss prejudice previously disclose suit federal court alabama provider health service needy patient allege pharmaceutical company overcharge plaintiff class similarly situate pharmaceutical purchase plaintiff program establish section public health service act company defendant file motion dismiss complaint numerous ground recently deny court previously disclose january doj notify federal court new orleans louisiana go intervene time pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid dismiss amend complaint file seal case administratively closed court seal lift state louisiana file amend complaint incorporate allegation contain seal amend complaint allegation contain seal amend complaint unknown april company name qui tam lawsuit nevada false claim act suit nevada attorney general intervene allege company inappropriately offer nominal pricing marketing pricing inducement certain customer fail comply obligation medicaid good price scheme relate arrangement company vigorously defend lawsuit governmental proceeding previously disclose company receive subpoena doj connection investigation company marketing selling activity include nominal pricing program sample company report receive cid attorney general texas company marketing selling activity relate texas previously disclose company receive cid attorney general texas ask additional information company marketing selling activity relate texas include respect certain nominal pricing program sample april company receive subpoena table content office inspector general district columbia connection investigation company interaction physicians district columbia maryland virginia november company receive letter request doj connection investigation company pricing pepcid september company receive subpoena illinois attorney general subpoena seek information relate repackage prescription drug previously disclose company receive letter doj advise existence qui tam complaint allege company violate certain rule relate calculation good price federal pricing benchmark calculation certain affect company medicaid rebate obligation company cooperate investigation company predict outcome investigation possible unfavorable outcome material adverse effect company financial position liquidity result operation addition time time federal state foreign regulator authority seek information practice pharmaceutical industry company business practice inquiry investigation discuss section feasible predict outcome inquiry february italian antitrust authority adopt measure commence formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ascertain company msd italy commit abuse dominant position virtue company refusal grant acs dobfar spa dobfar italian company voluntary license pursuant domestic legislation pass permit dobfar manufacture tienam imipenem cilastatin italy sale outside italy country patent protection applicable domestic rule expire exist company supplementary protection certificate spc provide company certain right respect manufacture sale tienam italy expire january hear italian antitrust authority hold june italian antitrust authority ica issue order impose interim measure require company grant license manufacture tienam italy pursuant icas order license grant dobfar limited right manufacture build supply stock tienam allow dobfar export tienam outside italy sell tienam product italy prior expiry spc november italian administrative court deny company appeal ica order proceeding ica ongoing vaccine litigation previously disclose company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mumps rubella include company mmr condition include autism inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimant proceed company knowledge intend proceed company company vigorously defend lawsuit previously disclose company party individual class action product liability lawsuit claim united states involve pediatric vaccine hepatitis vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december approximately active thimerosal relate lawsuit approximately plaintiff defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine state court case federal district court case schedule trial case dismiss case set trial dismiss certain dismissal appeal company vigorously defend table content lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation company successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period company aware numerous case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr vaccine cause autism spectrum disorder case refer precede paragraph dismiss bring plaintiff claim timely withdrawal vaccine court petition company party vaccine court proceeding petition bring department health human service patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration company astrazenecas case prilosec nexium patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company file patent infringement suit federal court company file andas generic omeprazole prilosec esomeprazole nexium similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product previously disclose january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax lose market exclusivity united states february company expect significant decline fosamax sale time federal court canada trial division issue decision refuse bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july merck sue federal court canada apotex seek damage lose sale generic weekly alendronate patent proceed january high court justice england wale hold patent company protect alendronate daily weekly product invalid united kingdom november court appeal england wale affirm rule high court justice england wale table content european country permit company seek approval generic product reference datum innovative product certain circumstance datum exclusivity regulation high court justice affirm decision regulatory authority datum weekly alendronate referenced company seek approval generic weekly alendronate product company file leave appeal judgment swedish administration court affirm grant swedish regulatory authority approval generic weekly alendronate product reference company data weekly alendronate approval company file similar case country previously announce company july opposition division opposition division european patent office epo render oral decision revoke company patent europe cover onceweekly administration alendronate august write opinion issue confirm oral decision revoking company patent september company file appeal decision hearing appeal schedule march decision proceeding typically render end hearing decision upheld company entitle market exclusivity fosamax major european market addition merck basic patent covering use alendronate challenge european country company unsuccessful country company lose exclusivity right fosamax country company defend alendronate weekly product major european market base patent october action australia challenge validity company australian patent onceweekly administration alendronate patent find invalid company appeal decision addition previously disclose japan proceeding file challenge validity company japanese patent onceweekly administration alendronate january company sue hitech pharmacal inc hitech amityville new york patent infringement response hitechs application fda seek approval generic version merck ophthalmic drug trusopt cosopt treat elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sue enforce patent cover active ingredient dorzolamide present trusopt cosopt merck elect enforce patent list fda cover combination dorzolamide timolol active ingredient cosopt lawsuit automatically stay fda approval hitech anda month adverse court decision whichever occur early patent covering dorzolamide provide exclusivity trusopt cosopt october include month pediatric exclusivity time company expect sale product decline case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent december court appeal federal circuit affirm decision trial court respect company patent infringement claim certain generic manufacturer omeprazole product trial schedule march company astrazeneca receive notice october ranbaxy laboratory limit ranbaxy file anda esomeprazole magnesium anda contain paragraph challenge patents nexium november company astrazeneca sue ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stay month april adverse court decision whichever occur early case finasteride anda file seek approval generic version propecia allege invalidity company patent company file patent infringement lawsuit district court delaware september trial schedule june table content europe company aware company seek registration generic losartan active ingredient cozaar company patent right losartan license pont nemour company pont company pont file patent infringement proceeding company portugal litigation july merck serve shareholder derivative suit file new jersey superior court hunterdon county company certain current officer director lawsuit seeks recover cancel compensation award company executive officer assert claim breach fiduciary duty waste unjust enrichment november individual shareholder deliver letter board allege company sustain damage company adoption change control separation benefit plan cic plan november shareholder demand board legal action board current member allegedly cause damage company respect adoption cic plan response demand letter independent member board determine november board meeting board shareholder request consideration remain consideration previously disclose july united states district court district new jersey grant motion company medco health solutions inc medco health certain officer director dismiss purport class action complaint involve claim relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit allegation complaint dismiss prejudice august court grant company motion dismiss prejudice relate shareholder derivative action plaintiff action appeal decision december court appeal circuit uphold district court decision dismiss class action complaint separate decision issue day court appeal uphold district court decision dismiss shareholder derivative suit send issue company board director properly refuse shareholder demand relate company treatment retail copayment district court reconsideration different legal standard previously disclose prior spinoff medco health company medco health agree settle class action basis series lawsuit assert violation erisa gruer case company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated medco health company agree propose settlement order avoid significant cost distraction prolong litigation propose class settlement agree plaintiff case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december district court hold hearing hear objection fairness propose settlement approve settlement determined number class member plan properly elect participate settlement settlement final appeal resolve certain class member plan indicate participate settlement case initiate plan individual remain pende southern district new york plaintiff case assert claim base erisa federal state law similar claim assert settle class member gruer case company medco health name defendant case table content notice appeal file appellate court hear oral argument december appellate court issue decision vacate district court judgment remand case district court allow district court resolve certain jurisdictional issue hear hold address issue february spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss note opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide note environmental matter company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost insurer site owner operator recalcitrant potentially responsible party previously disclose december virginia department environmental quality vadeq issue notice violation company elkton virginia facility air permit limit exceedance report facility result performance testing process train company settle matter vadeq agree million capital improvement site pay vadeq fine iii perform supplemental environmental project december company settle claim bring new jersey department environmental protection allege damage natural resource new jersey merck remediation site settlement company agree pay million donate acre land adjacent rahway river fund restoration project passaic river watershe groundwater contamination find company site item submission matter vote security holder applicable table content executive officer registrant age february richard clark age chief executive officer president june president merck manufacturing division responsible company manufacture information service operational excellence organization worldwide january chairman president chief executive officer medco health solutions inc medco health whollyowne subsidiary company january president medco health david anstice age august president human healthasia pacific responsible company prescription drug business asia pacific region japan australia new zealand company joint venture relationship scheringplough january president human health responsible company prescription drug business japan latin america canada australia new zealand company joint venture relationship scheringplough march president america human health responsible prescription drug division comprise human health company prescription drug business canada latin america company joint venture relationship scheringplough january president human health america responsible company human health business united states canada latin america celia colbert age january vice president secretary september assistant general counsel november willie deese age president merck manufacturing division responsible company global manufacturing procurement operational excellence function january senior vice president global procurement prior january deese senior vice president global procurement logistics glaxosmithkline plc caroline dorsa age august vice president treasurer responsible company treasury tax function provide financial support merck manufacturing merck research laboratory division human resource september vice president treasurer responsible company treasury tax function provide financial support asia pacific division table content kenneth frazi age december senior vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company richard henriques age august vice president controller responsible corporate controller group provide financial support human health operation united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller february responsible corporate controller group provide financial support human health canada latin america americas mvd peter kim age january president merck research laboratory mrl february executive vice president research development mrl judy lewent age august executive vice president chief financial officer responsible company strategic plan financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc subsidiary company january executive vice president chief financial officer president human health asia responsible financial corporate development function internal auditing corporate licensing company prescription drug business asia north asia south company joint venture relationship merck capital ventures llc february executive vice president chief financial officer april responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc adel mahmoud age september chief medical advisor vaccine infectious disease responsible represent company external medical policy government forum matter infectious disease vaccine president merck vaccines margaret mcglynn age august president merck vaccines global responsibility vaccine business include company sanofiaventis joint venture january president human health responsible prescription drug division hospital specialty product franchise comprise human health ushh manage care group ushh august executive vice president customer marketing sale ushh november senior vice president worldwide human health marketing table content chris scalet age january senior vice president global process service chief information officer cio responsible global share service human resource finance site service information service function enterprise business process redesign initiative march senior vice president information services cio responsible area information technology service include application development technical support voice datum communication computer operation worldwide prior march scalet senior vice president information technology cio international paper company global forest product paper packaging company bradley sheare age august president human health responsible entire prescription drug business comprise human health ushh january president human health responsible prescription drug division primary care product franchise comprise ushh march president human health responsible prescription drug division hospital specialty product franchise comprise ushh july vice president hospital marketing sale ushh joan wainwright age january vice president public affairs woldolsen age august president human health intercontinental responsible company prescription drug business europe middle east africa latin america canada worldwide human health marketing january president human healtheurope middle east africa responsible company prescription drug business europe middle east africa worldwide human health marketing officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security require information market information dividend incorporate reference company annual report stockholder require information number holder company common stock incorporate reference company annual report stockholder issuer purchase equity security month period end december follow issuer purchase equity security total number million total share purchase approx dollar value number average share share price pay publicly announce purchase period purchase share plan program plan programs october october november november december december total item select financial datum information require item incorporate reference datum fiscal year company include result year yearend position select financial datum table company annual report stockholder item management discussion analysis financial condition result operation information require item incorporate reference page company annual report stockholder item quantitative qualitative disclosure market risk information require item incorporate reference page begin caption financial instrument market risk disclosure company annual report stockholder table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december report date february pricewaterhousecooper llp independent register public accounting firm incorporate reference page respectively company annual report stockholder supplementary datum select quarterly financial datum incorporate reference datum contain condense interim financial datum table company annual report stockholder item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend effective management responsible establish maintain adequate internal control financial reporting term define exchange act rule management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december base criteria internal control integrate framework issue coso management assessment effectiveness internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm pricewaterhousecooper llp issue report management assessment effectiveness company internal control financial reporting incorporate reference company annual report stockholder change internal control financial reporting period cover report materially affect reasonably likely materially affect company internal control financial reporting item information iii item director executive officer registrant require information director nominee incorporate reference page company proxy statement annual meeting stockholder hold april information executive officer set forth document page table content require information audit committee financial expert incorporate reference head financial expert audit committee company proxy statement annual meeting stockholder hold april require information identification audit committee incorporate reference caption board committee companys proxy statement annual meeting stockholder hold april require information compliance section security exchange act incorporate reference caption section beneficial ownership report compliance company proxy statement annual meeting stockholder hold april company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcorporategovernance company intend post website amendment waivers code conduct print copy send charge stockholder request write chief ethic officer merck inc merck drive whitehouse station item executive compensation information require item incorporate reference page caption compensation director page begin caption summary compensation table page begin caption annual benefit payable merck inc retirement plans caption compensation committee interlock insider participation company proxy statement annual meeting stockholder hold april item security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference caption equity compensation plan information company proxy statement annual meeting stockholder hold april information respect security ownership certain beneficial owner management incorporate reference page caption security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april item certain relationship relate transaction information require item incorporate reference caption relationship outside firm caption indebtedness management company proxy statement annual meeting stockholder hold april item principal accountant fee service information require item incorporate reference page begin caption preapproval policy service independent register public accounting firm company proxy statement annual meeting stockholder hold april table content item exhibit financial statement schedule document file financial statement follow consolidated financial statement report independent register public accounting firm incorporate reference company annual report stockholder note document consolidate statement income year end december consolidated statement retain earning year end december consolidate statement comprehensive income year end december consolidated balance sheet december consolidate statement cash flow year end december note consolidated financial statement report pricewaterhousecooper llp independent register public accounting firm financial statement schedule schedule omit require applicable financial statement affiliate carry equity basis omit consider individually aggregate affiliate constitute significant subsidiary exhibit exhibit number description master restructuring agreement date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june restate certificate incorporation merck inc october incorporate reference form quarterly report period end september bylaw merck inc amend effective incorporate reference current report form date indenture date april merck inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck inc trust new york national association trustee incorporate reference exhibit registration statement form table content exhibit number description executive incentive plan amend effective february cid incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january cid incorporate reference annual report fiscal year end december merck inc deferral program amend restate december cid incorporate reference current report form date december incentive stock plan amend effective february cid incorporate reference annual report fiscal year end december incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december merck inc change control separation benefit plan incorporate reference current report form date november nonemployee directors stock option plan amend restate february cid incorporate reference form annual report fiscal year end december nonemployee director stock option plan amend april cid incorporate reference form quarterly report period end june nonemployee directors stock option plan amend april cid incorporate reference form quarterly report period end june supplemental retirement plan amend effective january cid incorporate reference annual report fiscal year end december retirement plan director merck inc amend restate june cid incorporate reference form quarterly report period end june management contract compensatory plan arrangement table content exhibit number description plan defer payment director compensation amend restate cid incorporate reference current report form date limited liability company agreement merck capital ventures llc date november cid incorporate reference annual report fiscal year end december offer letter merck inc peter kim date december cid incorporate reference annual report fiscal year end december amend restate license option agreement date july astra astra merck inc cid incorporate reference form quarterly report period end june kbi share option agreement date july astra merck inc merck holdings inc cid incorporate reference form quarterly report period end june kbie asset option agreement date july astra merck inc astra merck inc astra merck enterprises inc cid incorporate reference form quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical portion exhibit subject request confidential treatment file commission cid incorporate reference form quarterly report period end june second amend restate manufacturing agreement date july merck inc astra astra merck inc astra usa inc cid incorporate reference form quarterly report period end june limited partnership agreement date july usa kbi sub inc cid incorporate reference form quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical cid incorporate reference form quarterly report period end june management contract compensatory plan arrangement table content exhibit number description agreement incorporate define term date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical cid incorporate reference form quarterly report period end june computation ratio earning fix charge annual report stockholder portion incorporate reference document deem file subsidiary merck inc consent independent register public accounting firm cid contain report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer copy exhibit obtain stockholder write request direct stockholder service department merck inc box whitehouse station new jersey table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize merck inc date march richard clark chief executive officer president celia colbert celia colbert attorneyinfact pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date richard clark chief executive officer march president principal executive officer director judy lewent executive vice president march chief financial officer principal financial officer richard henriques vice president controller march principal accounting officer lawrence bossidy director march william bowen director march johnnetta cole director march william harrison director william kelley director march rochelle lazarus director march thomas shenk director march anne tatlock director samuel thi director march wendell week director march peter wendell director march celia colbert signing hereto sign document pursuant power attorney duly execute person name file security exchange commission exhibit document behalf person capacity date state person include majority director company celia colbert celia colbert attorneyinfact table content exhibit consent independent register public accounting firm consent incorporation reference registration statement form nos form nos merck inc report date february relate consolidated financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appear annual report stockholder incorporate reference annual report pricewaterhousecooper llp florham park new jersey march table content exhibit index exhibit number description master restructuring agreement date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june restate certificate incorporation merck inc october incorporate reference form quarterly report period end september bylaw merck inc amend effective incorporate reference current report form date indenture date april merck inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck inc trust new york national association trustee incorporate reference exhibit registration statement form executive incentive plan amend effective february cid incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january cid incorporate reference annual report fiscal year end december merck inc deferral program amend restate december cid incorporate reference current report form date december incentive stock plan amend effective february cid incorporate reference annual report fiscal year end december incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december management contract compensatory plan arrangement table content exhibit number description incentive stock plan amend restate february cid incorporate reference annual report fiscal year end december merck inc change control separation benefit plan incorporate reference current report form date november nonemployee directors stock option plan amend restate february cid incorporate reference form annual report fiscal year end december nonemployee director stock option plan amend april cid incorporate reference form quarterly report period end june nonemployee directors stock option plan amend april cid incorporate reference form quarterly report period end june supplemental retirement plan amend effective january cid incorporate reference annual report fiscal year end december retirement plan director merck inc amend restate june cid incorporate reference form quarterly report period end june plan defer payment director compensation amend restate cid incorporate reference current report form date limited liability company agreement merck capital ventures llc date november cid incorporate reference annual report fiscal year end december offer letter merck inc peter kim date december cid incorporate reference annual report fiscal year end december amend restate license option agreement date july astra astra merck inc cid incorporate reference form quarterly report period end june kbi share option agreement date july astra merck inc merck holdings inc cid incorporate reference form quarterly report period end june management contract compensatory plan arrangement table content exhibit number description kbie asset option agreement date july astra merck inc astra merck inc astra merck enterprises inc cid incorporate reference form quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical portion exhibit subject request confidential treatment file commission cid incorporate reference form quarterly report period end june second amend restate manufacturing agreement date july merck inc astra astra merck inc astra usa inc cid incorporate reference form quarterly report period end june limited partnership agreement date july usa kbi sub inc cid incorporate reference form quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical cid incorporate reference form quarterly report period end june agreement incorporate define term date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical cid incorporate reference form quarterly report period end june computation ratio earning fix charge annual report stockholder portion incorporate reference document deem file subsidiary merck inc consent independent register public accounting firm cid contain report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer exhibit merck inc subsidiarie computation ratio earning fix charge million ratio datum month end december year end december income continue operation taxis add subtract onethird rent interest expense gross interest capitalize net amortization equity income loss affiliate net distribution prefer stock dividend net tax earning continue operation onethird rent interest expense gross prefer stock dividend fix charge continue operation ratio earning fix charge continue operation purpose compute ratio earning consist income continue operation taxis onethird rent deem company representative interest factor inherent rent interest expense net amount capitalize equity income loss affiliate net distribution dividend prefer stock subsidiary company fix charge consist onethird rent interest expense report company consolidate financial statement dividend prefer stock subsidiary companiesexhibit financial section content financial review financial review description merck business description merck business merck global researchdriven pharmaceutical company overview discover develop manufacture market broad range competition health care environment innovative product improve human animal health operating result directly joint ventures merck sell product select joint venture affiliate information primarily drug wholesaler retailer hospital clinic capital expenditure government agency manage health care provider analysis liquidity capital resource health maintenance organization institution financial instrument market risk disclosure company professional representative communicate critical accounting policy matter effectiveness safety value product health care recently issue accounting standard professional private practice group practice manage cautionary factor affect future result care organization cash dividend pay common share common stock market price overview condense interim financial datum december merck unveil plan reclaim consolidate statement income leadership position pharmaceutical industry consolidated statement retain earning strategy merck focus improve research consolidate statement comprehensive income development productivity focus select consolidated balance sheet therapeutic area implement new commercial model consolidated statement cash flow deliver great value customer reduce overall note consolidated financial statement cost structure companywide management report merck new model design increase productivity audit committee report improve probability success prioritize report independent register public accounting company resource priority disease area firm alzheimer disease atherosclerosis cardiovascular disease compensation benefit committee report diabete novel vaccine obesity oncology pain sleep select financial data disorder therapeutic area carefully choose base set criterion include unmet medical need scientific opportunity commercial opportunity therapeutic area merck commit resource achieve research breadth depth develop bestinclass target differentiate product value highly patient payer physician company focus investment pursue specific mechanism follow select disease area antibiotic antifungal antiviral hepatitis virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize select opportunity outside area continue commercialize attractive clinical development candidate pipeline pursue appropriate external licensing opportunity merck report shareholder mercks latestage pipeline show strong progress million separation cost million biologic license application bla submission accelerate depreciation asset impairment cost food drug administration fda new manufacturing facility include action drug application nda file fda ponder end united kingdom okazaki japan kirkland additional fda filing anticipate expect canada albany georgia danville pennsylvania program phase iii quarter preclinical site okazaki menuma japan fda submission include gardasil company incur significantly large accelerate depreciation breakthrough vaccine help prevent cervical cancer charge associate action asset second lead cause cancer death women worldwide impairment charge associate abandonment zostavax vaccine reduce incidence shingle certain fix asset long business rotateq pediatric vaccine prevent rotavirus gastroenteritis result restructuring action company lead cause diarrhea infant young child plan close basic research center terling park united lead nearly death worldwide year kingdom incur additional accelerate depreciation cost february merck announce approval fda million respect site rotateq addition february merck announce additional charge approximately million billion fda accept bla gardasil grant expect record base estimate vaccine priority review designation time completion salesclosure facility february merck announce nda file previously discuss occur merck expect cost reduction fda januvia propose trademark program yield cumulative pretax saving compound know novel mechanism billion treatment type diabete accept standard review american jobs creation act ajca sign law merck anticipate additional fda filing october create temporary incentive vorinostat generic suberoylanilide hydroxamic december multinational repatriate acid saha compound histone deacetylase inhibitor accumulate income earn outside united states cancer intravenous prodrug aprepitant december connection ajca company treat chemotherapyinduced nausea vomiting repatriate billion result record improve commercial selling model merck continue income tax charge million charge streamline restructure marketing sale operation partially offset million benefit associate worldwide improve effectiveness generate great decision implement certain tax planning strategy efficiencies united states company previously disclose september merck reduce number sale representative promote announce voluntary worldwide withdrawal vioxx product percent versus historical level addition arthritis acute pain medication result company merck place emphasis active engagement key record charge pretax income million opinion leader accelerate development diffusion million tax adjustment net income scientific information devote additional resource utilize quarter include charge future legal technology demonstrate product value physician defense cost vioxx withdrawal process complete payer consumer increase influence cost associate withdrawal prescription decision united states approach line original amount record company result considerable productivity improvement pilot program expect low company december company establish spending brand percent reserve million solely future vioxx legal defense maximize sale performance provide additional support cost company spend million upcoming vaccine launch united states merck aggregate vioxx legal defense cost worldwide fourth redeploying sale representative currently promote quarter company record charge million major inline product support launch new vaccine increase reserve solely future legal defense cost november company announce phase relate vioxx million december global restructuring program design reduce reserve base certain assumption good company cost structure increase efficiency enhance estimate company believe time competitiveness initial step include reasonably estimate spend implementation new supply strategy merck earning common share assume dilution manufacturing division intend create lean include impact global restructuring program costeffective customerfocuse manufacturing model share net tax charge primarily associate year program merck plan ajca share additional reserve sell close manufacture site preclinical site establish solely future legal defense cost vioxx end eliminate approximately position litigation discuss companywide december approximately position company eliminate merck incur million cost associate global restructuring program comprise merck report shareholder competition health care environment antiretroviral regimen contain crixivan stocrin market company conduct business action merck work highly competitive highly regulated global effort independently partner public private health care cost containment continue exert pressure sector alike focus critical barrier access product pricing access medicine develop world need sustainable united states government expand health care financing increase international assistance additional access enact medicare prescription drug investment education training health infrastructure improvement modernization act sign capacity develop country law december prescription drug coverage begin increase focus privacy january new benefit support company issue country world include united states goal improve access medicine expand insurance united states government coverage preserve marketbase incentive pursue legislative regulatory initiative privacy pharmaceutical innovation time benefit include federal privacy regulation recently enact state ensure prescription drug cost control privacy law concern health personal information competitive pressure encourage appropriate use affect company operation medicine predict outcome address costcontainment pressure company legislative regulatory advocacy initiative company continue effort demonstrate medicine wellpositione respond evolve health care help save cost overall patient health care addition pricing environment market force flexibility company product portfolio certain company product face patent expiration encourage grow use medicine mitigate merck consider enter authorize generic agreement effect increase cost pressure allow company benefit outside united states difficult environment medicine available generic form encumber government costcontainment action company anticipate worldwide trend company work partnership payer allocate costcontainment continue result ongoing pressure scarce resource optimize health care outcome limit health care budget company continue potentially detrimental effect government policy sale successfully launch new product contribute health care growth access innovative medicine vaccine debate monitor reform new product policy support discovery development innovative product strategy enable maintain strong position benefit patient company work change economic environment government emerge market eastern europe latin america asia encourage increase operating result investment health improve citizen access sale medicine country european union worldwide sale decrease total recognize economic importance researchbase reflect decrease relate voluntary worldwide pharmaceutical industry value innovative medicine withdrawal vioxx offset revenue growth society work industry representative product growth reflect favorable effect european commission proposal complete single foreign exchange favorable effect price change market pharmaceutical improve competitive climate volume increase sale performance reflect variety mean include market deregulation strong growth singulair onceaday oral medicine indicate company commit improve access treatment chronic asthma relief symptom medicine enhance quality life people allergic rhinitis cancidas antifungal infection world african comprehensive hivaids partnership cozaarhyzaar high blood pressure high revenue achap botswana partnership government company relationship astrazeneca botswana bill melinda gates foundation azlp primarily drive nexium sale growth offset merck company foundationmerck inc support decline sale zocor high cholesterol botswanas response hivaid comprehensive domestic sale decline reflect unfavorable effect sustainable approach hiv prevention care treatment voluntary worldwide withdrawal vioxx support company initiate similar offset revenue growth product partnership people republic china focus initially foreign sale decline reflect unfavorable effect sichuan province help strengthen chinas response voluntary worldwide withdrawal vioxx hiv epidemic offset revenue growth product foreign catalyze access hiv medicine develop sale represent total sale country price reduction guideline company worldwide sale increase total announce merck make profit sale reflect favorable effect foreign exchange current hivaids medicine world poor country favorable effect price change volume decline hard hit pandemic offer hivaids sale unfavorably impact voluntary medicine significantly reduce price mediumincome worldwide withdrawal vioxx foreign sale represent country end patient total sale develop country treat merck report shareholder sale company product follow similar growth rate child take placebo study child take inhale steroid slow growth rate million child singulair placebo ocor fda approve new indication singulair fosamax accept review supplemental nda singulair cozaarhyzaar use prevention exerciseinduce bronchospasm singulair eib patient year age old december proscar merck receive approvable letter fda eib primaxin indication singulair merck currently discussion vasotecvaseretic fda determine additional data revision cosopttrusopt application necessary obtain approval cancidas indication maxalt august merck announce fda propecia approve singulair symptom perennial allergic vioxx rhinitis yearround allergy adult child vaccinesbiological month age old january merck announce new indication singulair treat symptom seasonal allergic rhinitis asthmatic patient launch new indication present net discount return launch country company product include therapeutic preventive respiratory therapy approve treatment asthma agent generally sell prescription treatment seasonal allergic rhinitis asthmatic patient indication human disorder zocor merck large singulair treatment seasonal allergic rhinitis selling atherosclerosis product fosamax fosamax plus grant united states late merck osteoporosis product treatment case merck expect seek new indication singulair acute fosamax prevention osteoporosis cozaarhyzaar asthma respiratory syncytial bronchiolitis vasotec company significant hypertensionheart failure product singulair leukotriene receptor antagonist global sale cozaar companion agent hyzaar respiratory product treatment chronic asthma combination cozaar diuretic hydrochlorothiazide relief symptom allergic rhinitis proscar urology treatment hypertension strong reach product treatment symptomatic benign prostate billion increase enlargement primaxin cancidas antibacterialantifungal cozaar hyzaar compete fastestgrowe class product cosopt trusopt largestselle antihypertensive market angiotensin antagonist aiia ophthalmological product maxalt acute migraine product cozaarhyzaar continue largestselling brand aiia propecia product treatment male pattern hair loss europe second frequently prescribe aiia vaccinesbiological include varivax live virus united states vaccine prevention chickenpox mmr pediatric early october fda approve new tablet vaccine measle mump rubella pneumovax hyzaar new dosage offer oncedaily vaccine prevention pneumococcal disease efficacy cozaar lowdose diuretic new recombivax vaccine prevention hepatitis formulation address need titration flexibility primarily include sale human intermediate step cozaar hyzaar pharmaceuticals pharmaceutical animal health supply filing new formulation outside united states sale company joint venture revenue occur include united companys relationship azlp primarily relate sale kingdom germany france italy nexium prilosec revenue azlp billion april fda approve new indication hyzaar billion billion base losartan intervention endpoint reduction respectively life trial reduction risk stroke patient singulair merck onceaday oral respiratory medicine hypertension leave ventricular hypertrophy lvh indicate treatment chronic asthma relief evidence benefit apply black patient symptom allergic rhinitis continue strong performance global sale fosamax prescribe medicine reflect continued demand asthma medication worldwide treatment postmenopausal male new indication perennial allergic rhinitis united glucocorticoidinduce osteoporosis billion state total sale singulair billion increase merck enhance increase osteoporosis franchise addition fosamax plus december merck announce label change new product provide proven power fosamax singulair incorporate positive result clinical reduce risk hip spine fracture plus study show child asthma take singulair assurance offer minimum vitamin intake consistent recommend guideline available united states early august merck report shareholders european commission grant marketing authorization vomiting associate moderately highly emetogenic product know europe fosavance approval cancer chemotherapy maxalt treat migraine pain invanz fosamax plus extend patent fosamax treatment select moderate severe infection adult fosamax plus important innovation osteoporosis propecia male pattern hair loss contribute treatment help satisfy unmet medical need merck total sale revenue result estimate woman age company relationship azlp primarily relate sale woman age get adequate intake vitamin nexium vitamin insufficiency associate reduce calcium global sale cancidas oncedaily antifungal medicine absorption bone loss increase risk fracture strong reach million increase additionally new oneyear extension result strong result drive new indication fact fosamax actonel comparison trial study show receive fda october empirical therapy fosamax deliver significantly great increase bone presume fungal infection febrile neutropenic patient mineral density bmd hip spine proscar merck urology product treatment risedronate year increase bmd see symptomatic benign prostate enlargement patent fosamax great compare risedronate year lose market exclusivity united states june year fosamax deliver superior reduction result company expect significant decline bone turnover risedronate significantly great proscar sale time basic patent proscar effect month treatment cover propecia propecia protect additional previously disclose january court patent expire october appeals federal circuit washington find report merckscheringplough partnership company patent claim onceweekly administration global sales zetia vytorin aggregate reach fosamax invalid company exhaust option billion global sale zetia market ezetrol outside appeal decision base court appeal united states cholesterolabsorption inhibitor reach decision fosamax lose market exclusivity unite billion increase global sale state february company expect significant vytorin market inegy outside united states reach decline fosamax sale time additionally sale billion vytorin single tablet cholesterol fosamax decline certain country treatment provide ldl cholesterol lower dual patent expire inhibition cholesterol production absorption vytorin zocor mercks statin modifying cholesterol achieve approve united states july demonstrate worldwide sale billion decrease consistent growth sale zocor affect increase competition november merckscheringplough partnership united states generic competition market announce commencement patient enrollment outside united states currently zocor available largescale clinical outcome trial improveit improve percent manage care live percent reduction outcome vytorin efficacy international trial target manage care contract renew trial evaluate effectiveness vytorin compare june zocor lose market exclusivity zocor simvastatin treat approximately high united states company expect significant decline risk patient coronary artery disease present acute zocor sale time global sale zocor coronary syndrome clinical trial site open estimate billion fullyear north america europe product experience growth include company record result interest cancida treat certain lifethreatening fungal infection merckscheringplough partnership equity income primaxin treatment bacterial infection cosopt treat affiliate glaucoma emend prevention acute delay nausea cost expense million change change aterial production marketing administrative research development restructuring costs equity income affiliate income expense net great merck report shareholder material production close preclinical site end okazaki material production cost increase menuma japan connection global restructuring compare decline sale include increase program addition decrease reflect impact unfavorable effect inflation increase million licensing expense initial payment volume increase attributable million record certain disclose research collaboration million primarily relate global restructure program acquire research expense acquisition aton million represent impairment charge associate pharma inc partially offset decrease abandonment certain fix asset long increase research development activity support business result restructure merck pipeline action remain million represents accelerate december merck submit bla fda depreciation associate merck plan sell close gardasil quadrivalent human papillomavirus type own manufacturing facility note variance recombinant vaccine company vaccine protect cost relative sale decline reflect impact type human papillomavirus hpv type item note unfavorable effect account estimate cervical cancer sale associate voluntary worldwide withdrawal case type account estimate vioxx genital wart case cervical cancer result approximately material production cost increase death worldwide year united states compare sale growth rate include increase estimate new case cervical cancer diagnose unfavorable effect inflation unfavorable effect approximately death exchange increase volume increase estimate million woman united states cost relative sale growth reflect unfavorable age expect age range effect associate voluntary worldwide withdrawal initial indication gardasil vioxx impact change product mix gross margin october merck present result future compare study phase iii efficacy study gardasil women restructuring charge note aged year datum present infectious impact voluntary worldwide withdrawal vioxx disease society america idsa annual meeting report unfavorable effect gross margin gardasil prevent highgrade cervical pre cancer noninvasive cervical cancer cin ais marketing administrative associate hpv type primary analysis marketing administrative expense decrease compare gardasil placebo woman infect include decrease unfavorable effect hpv enrollment remain free inflation unfavorable effect exchange infection completion sevenmonth vaccination decline volume decrease primarily cost regiman receive dose gardasil woman record million voluntary worldwide follow average year enrollment withdrawal vioxx note million case cin ais observe vaccine group establishment reserve solely legal defense cost compare case placebo group vioxx litigation partially offsetting decrease cin cervical intraepithelial neoplasia additional reserve million vioxx legal defense cost moderategrade lesion cervix cin represents record current year cost require highgrade lesion cis carcinoma situ immediate prepare launch new investigational vaccine precursor invasive squamous cell cervical cancer ais maintain activity support merck inline product early development adenocarcinoma glandular cancer roll new product indication critical outcome datum cervix globally secondary analysis present idsa evaluate marketing administrative expense increase incidence cin ais start day include increase unfavorable effect administration dose woman primary inflation unfavorable effect exchange analysis group woman increase volume increase reflect impact infect hpv hpv vaccination period additional million reserve record solely future woman violate protocol significant way legal defense cost vioxx litigation million example miss certain protocol visit estimate cost undertake voluntary worldwide include average woman follow withdrawal vioxx approximately year time enrollment research development group gardasil reduce risk develop highgrade research development expense decrease cervical precancer noninvasive cervical cancer cin include decrease unfavorable effect ais associate hpv inflation decline volume include case observe vaccine group compare accelerate depreciation cost million relate placebo group closure basic research center locate terling park february merck announce fda united kingdom million associate plan accept bla gardasil investigational sell cervical cancer vaccine give priority review agency priority designation intend product address unmet mercks report shareholder medical need prescription drug user fee act lanilide hydroxamic acid new class antitumor agents blas file fda goal review act blas inhibits histone deacetylase study designate priority review month receipt patient advance refractory cutaneous tcell lymphoma fda inform merck review goal date june ctcl experience partial response physician assessment submission fda december merck percent reduction overall disease burden primary submit application gardasil additional regulatory endpoint study result present agency include australia mexico brazil annual meeting american society clinical oncology argentina taiwan singapore orlando florida february company announce ctcl type nonhodgkin lymphoma slowgrowe glaxosmithkline gsk enter crosslicense form cancer bodys white blood cell settlement agreement certain patent right relate hpv know tlymphocyte tcell malignant ctcl vaccine pursuant agreement gsk receive affect patient unite state upfront payment royalty company base new case report year sale gardasil development launch september merck present study phase agreement resolve compete intellectual property claim datum company dpp inhibitor januvia propose relate company gsk vaccine candidate trademark sitagliptin potential new approach addition merck enter license agreement treatment type diabete annual meeting collaboration csl limited relate technology european association study diabetes easd gardasil gardasil subject thirdparty study show januvia significantly improve licensing agreement glycemic control patient primarily mildtomoderate september fda approve proquad measle hyperglycemia patient severe hyperglycemia mump rubella varicella okamerck virus vaccine live compare placebo study januvia proquad combination vaccine simultaneous vaccination generally welltolerate february merck measle mumps rubella varicella child announce nda januvia accept standard month year age proquad combine review fda merck expect fda action nda establish merck vaccine mmr measles mumps midoctober rubella virus vaccine live varivax varicella virus announce december merck develop vaccine live okamerck march centers mka combination januvia metformin disease control cdc announce rubella german treatment type diabetes measle long public health threat united announce december merck track state time merck sole manufacturer vaccine quarter promise drug phase iii protect rubella measle mump development diabete insomnia high cholesterol heart varicella united states disease hivaids phase iii candidate include august merck vaccine hepatitis vaqta follow approve fda use child month age gaboxadol unique mechanism merck alliance old previously vaqta approve use people lundbeck potential provide benefit year age old exist therapy respect sleep quality nextday february merck announce approval effect fda rotateq pentavalent vaccine protect mka mkb hold significant promise rotavirus gastroenteritis rotateq oral threedose liquid address critical need lipidcholesterol management vaccine contain human serotype mka represent novel approach treat hdlc merck submit application licensure triglyceride combine merck extend release niacin rotateq australia mexico canada countries asia mkb combine mka prove latin america sanofi pasteur msd joint benefit simvastatin potentially reduce risk coronary venture heart disease statin provide june fda accept standard review bla expect new class anti zostavax mercks investigational vaccine prevention retroviral effective inhibit integrase enzyme herpe zoster commonly know shingles adult necessary survival hiv february merck year age old sanofi pasteur msd submit announce interim result doserange phase trial application licensure zostavax merck show oral investigational submit application licensure zostavax medication dose study australia canada countries asia latin america orally twice daily combination optimize background february fda extend review month therapy obt great antiretroviral activity placebo late obt study result show merck announce result phase combination obt generally welltolerate open label study vorinostat investigational oral suberoy patient merck report shareholder advance hiv infection fail antiretroviral identify new biomarker atherosclerotic disease therapy art virus resistant drug progression use development cardiovascular available class oral art compound merck pipeline agreement include limited active art option treatment result research collaboration year present annual conference retrovirus october agensys inc cancer biotechnology opportunistic infection company merck announce form global merck continue remain focused augment alliance jointly develop commercialize agspsca internal research effort capitalize growth opportunity agensys fully human monoclonal antibody mab prostate range research collaboration preclinical clinical stem cell antigen psca agreement grant merck world compound technology transaction drive wide right agspsca exclusive license psca near longterm growth company complete proprietary target right therapeutic transaction broad range therapeutic diagnostic product develop alliance category include neuroscience obesity oncology october merck bristolmyers squibb earlystage technology transaction merck currently bms jointly announce sign separate license evaluate opportunity actively agreement international partnership microbicide monitor landscape range target acquisition develop new antiretroviral compound potential meet company strategic criterion highlight microbicide protect woman hiv agreement mark year include time pharmaceutical company license anti merck bioxell enter agreement hiv compound development microbicide class develop new treatment sepsis inflammatory drug early development compound disorder new class antiretroviral know entry inhibitor june vical incorporate exercise option compound bind directly hiv bind ccr amendment exist research collaboration receptor design prevent hiv efficiently license agreement grant merck right use vical enter host cell prevent infection patent nonviral gene delivery technology cancer vaccine company bm report october application fda issue approvable letter pargluva bmss investiga merck vertex pharmaceutical incorporate announce tional oral medicine treatment type diabete june initiation additional phase clinical study request additional safety information address fully small molecule inhibitor aurora kinases aurora cardiovascular safety profile pargluva datum requirement kinase implicate onset progression human cause significant delay product launch leukemia result bms merck terminate collaborative agreement sumitomo pharmaceutical ltd sumitomo merck pargluva right pargluva backup sign agreement june collaborate compound pargluva return bms december lurasidone atypical antipsychotic compound currently phase development treatment schizophrenia follow chart reflect company current research chronic disable severe mental illness pipeline february candidate show phase iii agreement sumitomo grant merck include specific product candidate show phase affiliate exclusive license part include advanced compound specific world japan china korea taiwan mechanism give therapeutic area backup compound june merck announce agreement regardless phase development additional indication metabasis therapeutic research develop therapeutic area additional line extension commercialize novel small molecule therapeutic formulation inline product show company potential treat disease include type diabetes program generally design focus development hyperlipidemia obesity activation enzyme novel medicine address large unmet medical need liver call ampactivated protein kinase announce december company intend focus july merck geron corporation announce research effort primarily follow priority area agreement develop cancer vaccine telomerase alzheimer disease atherosclerosis cardiovascular disease telomerase enzyme active cancer cell diabete novel vaccine obesity oncology pain sleep maintain telomere length end chromosome disorder activity allow cancer grow metastasize long period time september foxhollow technology merck announce formation novel pharmacogenomic collaboration collaboration focus analyze atherosclerotic plaque remove patient artery mean merck report shareholder research development expense increase research pipeline include increase unfavorable effect hase inflation unfavorable effect exchange lzheimer disease increase volume reflect company ongoing arthritis commitment basic clinical research atherosclerosis impact licensing agreement acquire research development discuss cancer agensys research development pharmaceutical industry inherently longterm process follow datum multi cancer vaccine year trend company research development cardiovascular disease spending period compound annual diabetes growth rate research development research development expenditure endocrine millions flu vaccine glaucoma insomnia obesity nastech pyy osteoporosis pain neurogen parkinson disease psychiatric disease respiratory disease aureus vaccine hase rthritis cancer ctcl vorinostat endocrine hiv vaccine hpv vaccine hypertension obesity osteoporosis pain pediatric vaccine psychiatric disease lurasidone stroke ono urinary incontinence hase iii restructuring cost id restructuring cost million million atherosclerosis mkb mka respectively include separation cinv cost associate merck plan eliminate approximately diabetes mka position companywide end fourth insomnia gaboxadol quarter merck incur million separation cost nder regulatory review associate global restructuring program relate cervical cancer separation cost associate elimination genital wart gardasil approximately position december shingles zostavax comprise actual headcount reduction elimination diabete januvia contractor vacant position estimate pprovable future termination roughly position rthritispain arcoxia probable reasonably estimate december note approval steoporosis fosamax plus costreduction initiative announce pediatric vaccine proquad october complete end company approval eliminate position company complete similar otavirus gastroenteritis rotateq program position eliminate december result restructuring action icensed alliance acquisition pipeline company record restructuring cost million ultiple license include csl ltd million erck discussion licensing partner plan compoundmerck report shareholder equity income affiliate income expense net equity income affiliate reflect performance decrease income expense net primarily company joint venture partnership return azlp reflect million gain sale increase equity income affiliate primarily company percent equity stake european joint venture reflect successful performance zetia vytorin johnson johnson realize gain merckscheringplough partnership high partnership company investment portfolio record return azlp relative increase transaction primary driver increase equity income affiliate reflect successful income expense net performance zetia merckscheringplough partnership high partnership return azlp earning million share amount hange hange ncome continue operation sale net income average total asset earning common share assume dilution continue operation taxis income earning common share company effective income tax rate earning common share assume dilution continue high tax rate operation decline compare decline reflect net tax charge primarily relate company reflect impact net tax charge decision repatriate billion foreign earning restructuring cost record unfavorable impact accordance ajca result company voluntary worldwide withdrawal vioxx record income tax charge million taxis income relate repatriation charge distribution sale equity income partially offset million benefit associate decision implement certain tax planning strategy net tax charge result increase percentage point effective tax rate year change mix domestic foreign income unfavorable impact income tax rate partially offset increase tax rate tax impact restructuring cost low tax rate result change mix domestic foreign income include impact vioxx withdrawal include impact restructuring cost wholesaler distribution program income continue operation income continue operation decline compare decline income continue select joint venture affiliate information operation percentage sale expand research base realize synergy decrease percentage combine capability opportunity asset company sale ratio compare reflect unfavorable impact form number joint venture note voluntary worldwide withdrawal vioxx financial statement information impact global restructuring charge record company scheringplough corporation percentage sale include scheringplough enter agreement create separate implementation new wholesaler distribution program net equallyowne partnership develop market united income percentage average total asset state new prescription medicine cholesterol management respiratory therapeutic area cholesterolmanagement partnership agreement expand include country world exclude japan ezetimibe new class cholesterol lower agent launch united states zetia market ezetrol outside united states report merckscheringplough partnership global sale zetia total billion billion merck report shareholder million july combination product contain segment sell transaction complete active ingredient zetia zocor approve divestiture merial interest poultry genetic business united states vytorin market lnegy outside comparative purpose amount present united states vytorin approve country respectively include revenue outside united states global sale vytorin earn poultry genetic business billion million result merck pasteur merieux connaught sanofi company interest merckscheringplough pasteur establish own joint venture market partnership record equity income affiliate merck vaccines europe collaborate development recognize income million million combination vaccine distribution europe september loss million sanofi pasteur msd spmsd mercks vaccine joint venture company enter agreement astra sanofi pasteur enter letter undertake lou astra develop market astra product united european medicines agency agency concern states company astra form equally longterm efficacy hepatitis component own joint venture develop market hexavac hepatitis component hexavac astras new prescription medicine united states manufacture merck lou require relevant include prilosec class medication know suspension hexavac license suspension proton pump inhibitor slow production acid hexavac distribution recall hexavac product cell stomach lining recall hexavac number noneu country company astra restructure joint surveillance program possible future revaccination venture company acquire astras interest spmsd market sell hexavac joint venture rename kbi inc kbi contribute kbis notify merck reserve right operate asset new limited partnership name astra seek damage merck defend indemnify pharmaceutical partnership company hold harmless merck event party claim maintain limited partner interest partnership rename september european medicine agency astrazeneca azlp exclusive distributor emea initiate formal review longterm efficacy product kbi retain right hepatitis vaccine hbvaxpro hepatitis merck earn ongoing revenue base sale current component hepatitis bhib combination vaccine future kbi product revenue billion procomvax product market sell spmsd billion billion european territory sell different respectively primarily relate sale nexium prilosec name merck assessment report prepare emea addition merck earn certain partnership return committee medicinal product human use chmp record equity income affiliate return include recommend limitation use product priority return provide partnership agreement recommendation merck response consider variable return base sale certain chmp meeting february astra usa inc products preferential return represent sale joint venture product follow merck share undistribute azlp gaap earning return aggregate million million million respectively million result reflect low preferential return primarily result epatitis vaccine impact generic competition prilosec viral vaccines merck rhnepoulenc sanofiaventis vaccines combined animal health poultry genetic business form merial limited merial fully integrate merck form joint venture johnson animal health company standalone joint venture johnson develop market broad range nonprescrip equally own party merial provide comprehensive tion medicine consumer own joint range pharmaceutical vaccine enhance health venture expand europe canada wellbeing performance wide range animal specie march merck sell equity stake sale joint venture product follow european joint venture johnson johnson million record million gain income expense million net merck continue benefit royalty certain ipronil product product regain right potential future avermectin product product switch prescription overthecounter status product europe sale joint venture product follow poultry genetic business consist segment domestic turkey layer segment divest million respectively broiler foreign turkey astrointestinal product product include sale european joint venture march mercks report shareholder capital expenditure analysis liquidity capital resource capital expenditure billion billion merck strong financial profile enable company fully expenditure united states million fund research development focus external alliance billion expenditure support inline product maximize upcoming launch include million production facility million provide significant cash return shareholder cash research development facility million provide operating activity billion continue environmental project million administrative company primary source fund finance capital safety general site project capital expenditure approve expenditure treasury stock purchase dividend pay spend december million stockholder december total worldwide capital expenditure estimate billion cash investment billion include billion depreciation billion billion cash cash equivalent shortterm investment billion million respectively billion longterm investment apply locations united states total depreciation october ajca sign law ajca includes accelerate depreciation million create temporary incentive december associate global restructuring plan million multinational repatriate accumulate income earn associate closure terling park basic research outside united states december center note company incur significantly large connection ajca company repatriate accumulate depreciation charge result billion result company record restructuring action income tax charge million taxis income relate repatriation million pay capital expenditure million pay quarter million december approximately billion ajca repatriation invest fully collateralized overnight repurchase agreement include short term investment consolidate balance sheet quarter company begin reinveste repurchase agreement balance short longterm investment select datum million orke capital total debt total liability equity cash provide operation total debt enable execution ajca repatriation company change mix investment longterm shortterm result significant increase work capital december work capital level adequate meet operating requirement company ratio total debt total liability equity cash provide operation total debt reflect strength company operate cash flow ability company cover contractual obligation companys contractual obligation december follow payment period million total urchase obligation loan payable current portion longterm debt longterm debt operating lease merck report shareholder purchase obligation consist primarily good service research development extent dollar value enforceable legally binding include obligation cash flow diminish result strengthen dollar minimum inventory contract research development company ability fund research dollarbase advertising research contract include milestone strategic initiative consistent level impaired payment contingent future event loan payable company establish revenue hedge balance sheet current portion longterm debt include million note risk management program protect volatility future final maturity annual basis foreign currency cash flow change fair value cause repurchase holder option volatility foreign exchange rate remarkete agent remarkete redeem objective revenue hedging program reduce company loan payable current portion longterm debt potential longerterm unfavorable change foreign reflect million longdate note subject exchange decrease dollar value future cash flow repayment option holder annual basis derive foreign currency denominate sale primarily loan payable include billion commercial paper euro japanese yen achieve objective company issue foreign subsidiary billion commercial partially hedge anticipate thirdparty sale paper borrowing facility establish october provide expect occur planning cycle typically fund portion company ajca repatriation year future company layer hedge require funding obligation relate company time increase portion sale hedge get pension postretirement benefit plan expect close expect date transaction material probable hedge transaction occur portion sale december company increase capacity hedge base assessment costbenefit profile shelf registration statement file security consider natural offset exposure revenue exchange exchange commission sec issue debt security rate volatility correlation cost hedge additional billion february company issue instrument hedge anticipated sale specify billion tenyear note shelf component portfolio similarly denominate foreign remain capacity company shelf registration currencybase sale transaction respond statement approximately billion hedge risk manner merck manage february company establish billion anticipate transaction exposure principally purchase local year revolve credit facility provide backup liquidity currency option provide company right commercial paper borrowing facility general corporate obligation sell foreign currency future purpose company draw funding predetermine price dollar strengthen relative facility currency hedge anticipate sale total change companys longterm credit rating assign moodys option cash flow fully offset decline expect future standard poor respectively dollar cash flow hedge foreign currency sale rating continue allow access capital market conversely dollar weaken option value flexibility obtain fund competitive term company reduce zero company benefit increase continue maintain conservative financial profile total cash value anticipate foreign currency cash flow investment billion exceed sum loan weak dollar result net benefit market payable longterm debt billion company value company hedge decline longterm credit rating remain million million respectively uniform rate nonfinancial corporation despite strong financial weaken dollar december profile certain contingent event realize market value determine foreign discuss note material adverse impact exchange option pricing model hold factor company liquidity capital resource company exchange rate constant merck principally use participate offbalance sheet arrangement purchase local currency option uniform weaken involve unconsolidated subsidiary provide finance dollar yield large overall potential loss potentially expose company unrecorde financial market value option sensitivity measurement obligation assume change foreign currency relative july board director approve purchase dollar affect foreign currency relative time billion merck share total treasury dollar predictive nature company stock purchase program billion believe threshold reflect reasonably possible near december billion remain term change merck major foreign currency exposure stock repurchase authorization approve merck board relative dollar cash flow contract director report operating activity consolidate statement cash flow financial instrument market risk disclosure primary objective balance sheet risk management foreign currency risk management program protect dollar value foreign currency dollar functional currency company denominate net monetary asset effect volatility foreign subsidiary significant portion company foreign exchange occur prior conversion revenue denominate foreign currency merck rely dollars merck principally utilize forward exchange sustain cash flow generate foreign source contract enable company buy support longterm commitment dollarbase merck report shareholder sell foreign currency future fix exchange rate company investment portfolio include cash economically offset consequence change foreign equivalent shortterm investment december exchange dollar cash flow derive include repurchase agreement market value net asset merck routinely enter contract fully significantly impact change interest offset effect exchange exposure denominate rate market value company medium longterm develop country currency primarily euro japanese fixedrate investment modestly impact change yen exposure develop country currency interest rate change medium longterm interest company enter forward contract limited rate significant impact market value basis deem economical base company fixedrate borrowing generally long costbenefit analysis consider magnitude maturity sensitivity analysis measure potential change exposure volatility exchange rate cost market value company investment debt hedge instrument company minimize effect relate swap contract change interest rate indicate exchange monetary asset liability manage percentage point increase interest rate operating activity net asset position local level december positively impact company periodically use forward contract hedge net aggregate market value instrument change fair value certain foreign currency denominate million million respectively percentage availableforsale security attributable fluctuation foreign point decrease december currency exchange rate sensitivity analysis change negatively impact net aggregate market value value dollar foreign currency denominate million million respectively increase derivative investment monetary asset liability sensitivity attributable change mix investment indicate dollar uniformly weaken longterm fix rate shortterm variable rate currency exposure company december december fair value company debt income continue operation taxis determined pricing model reflect percentage point decline million merck net short shift appropriate yield curve fair value position relative major foreign currency company investment determine combination consideration forward contract uniform weakening pricing duration model dollar yield large overall potential net loss earning exchange december critical accounting policy matter company net long position relative major foreign consolidated financial statement include certain amount currency consideration forward contract base management good estimate judgment uniform strengthen dollar estimate determine item provision reduce income continue operation taxis sale discount return depreciable amortizable life million measurement assume change recoverability inventory produce preparation product foreign currency relative dollar affect launch amount record contingency environmental foreign currency relative dollar liability reserve pension postretirement predictive nature company believe threshold benefit plan assumption taxis income reflect reasonably possible nearterm change merck uncertainty inherent estimate actual result differ major foreign currency exposure relative dollar estimate application follow accounting cash flow contract report operating policy result accounting estimate potential activity consolidate statement cash flow significant impact financial statement interest rate risk management revenue recognition addition revenue hedge balance sheet risk revenue sale product recognize title management program company use interest rate risk loss pass customer revenue domestic swap contract certain investing borrowing transaction pharmaceutical sale recognize time shipment manage net exposure interest rate change foreign subsidiary vaccine sale reduce overall cost borrowing company use revenue recognize time delivery recognition leverage swap general leverage revenue require reasonable assurance collection investment activity principal capital risk sale proceed completion performance obligation december company party pay domestically sale discount issue customer direct float receivefixed interest rate swap contract designate discount pointofsale indirectly fair value hedge fixedrate note mature intermediary wholesale purchaser know chargeback respectively notional amount swap indirectly form rebate additionally sale generally match hedge fixedrate note limited right return certain condition million million million respectively revenue record net provision sale discount swap effectively convert fixedrate obligation float return establish time sale rate instrument cash flow contract report operating activity consolidate statement cash flow merck report shareholder subsequent expiration date generally month provision aggregate indirect customer discount month product expiration cover chargeback rebate chargeback discount estimate provision return base historical occur contract customer purchase directly experience actual return additionally company intermediary wholesale purchaser contract consider factor level inventory distribution customer generally purchase product contract price channel product date expiration period product plus markup wholesaler wholesaler turn discontinued entrance market additional charge company difference price generic competition change formulary launch initially pay wholesaler contract price pay thecount product product return wholesaler customer provision chargeback provision actual return approximately base expect sellthrough level company net sale wholesale customer contract customer distribution program wholesaler estimate wholesaler inventory level rebate amount implement company incent wholesaler align owe base definitive contractual agreement legal purchase underlie demand maintain inventory requirement private sector public sector medicaid specified level term program allow benefit provider final dispense product wholesaler earn fee provide visibility pharmacy benefit plan participant provision base inventory level achieve certain performance expect payment drive patient usage parameter inventory management customer service contract performance benefit provider customer level reduce shortage claim reduce product return medicare prescription drug improvement information provide wholesaler distribution modernization act commonly refer medicare program include item sale trend inventory effective january company hand onorder quantity product return anticipate medicare material impact wholesaler generally provide mention result operation datum company regulatory requirement company assume firstin firstout movement report lot level information manufacturer level inventory supply chain purpose estimate information need determine remain shelf life aggregate indirect customer discount accrual addition original sale date inventory give current wholesaler company use historical customer segment mix adjust inventory level generally month know event order estimate expect provision company believe collection order lot information amount accrue aggregate indirect customer discount wholesale customer limited use estimate evaluate quarterly basis comparison sale discount return information provide wholesaler customer amount accrue adjustment record trend inventory produce preparation significant event indicate change estimate product launches provision appropriate company capitalize inventory produce preparation company continually monitor provision product launch sufficient support initial market demand aggregate indirect customer discount material typically capitalization inventory begin adjustment estimate associate aggregate indirect relate product candidate phase iii clinical trial customer discount provision consider high probability regulatory approval summarize information change aggregate december inventory produce preparation indirect customer discount accrual follow product launch consist vaccine product phase iii clinical trial new formulation exist vaccine product new compound type diabete alance january company continue monitor status respective current provision product regulatory approval process adjustment relate prior year company generally disclose specific timing payment regulatory approval company aware specific alance december risk contingency normal regulatory approval process specific issue identify accrual chargeback reflect direct reduction research process relate safety efficacy manufacturing account receivable accrual rebate accrue marketing labeling relate inventory generally expense accrue balance relative provision capitalize significant issue respect include account receivable accrue current product expiry date inventory liability million billion respectively impact stage completion company manage december million million level inventory stage optimize shelf life respectively december inventory relation anticipate market demand order company maintain return policy allow avoid product expiry issue shelf live substantially customer return product specify period prior product range minimum year anticipate future sale merck report shareholder product support realization inventory value follow actual cost incur company inventory shelf life sufficient meet initial product launch time development company legal defense requirement strategy structure light scope vioxx addition company produce inventory preparation litigation number case bring launch arcoxia united states arcoxia company cost outcome complete trial launch country europe latin america asia anticipate timing progression relate cost pretrial africa additionally company continue work activity trial vioxx product liability lawsuit regulatory agency countrie registration event schedule trial expect occur material launch arcoxia country october inherent inability company receive approvable letter fda predict ultimate outcome trial limit companys company nda arcoxia fda inform ability reasonably estimate legal cost end company letter approval nda company continue monitor legal defense issue additional safety efficacy datum arcoxia cost review adequacy associate reserve require outside united states merck continue work company currently anticipate number vioxx local regulatory agency review adjust prescribe product liability lawsuit try company information contain arcoxia label country predict timing trial respect vioxx minimum shelf life arcoxia approximately shareholder lawsuit company believe year anticipate worldwide market demand country meritorious defense vioxx lawsuit vigorously arcoxia approve support value defend view inherent difficulty predict inventory capitalize buildup inventory arcoxia ing outcome litigation particularly inventory produce preparation product launch claimants claimant seek indeterminate damage material effect company liquidity company unable predict outcome matter time reasonably estimate possible loss contingency environmental liability range loss respect vioxx lawsuit company company involve claim legal establish reserve potential liability proceeding nature consider normal business relate vioxx litigation include product liability intellectual property commercial company party number proceeding bring litigation additional matter antitrust action comprehensive environmental response note financial statement information compensation liability act commonly know company record accrual contingency superfund legitimate claim contribution assert probable liability incur liability initially accrue base estimate reasonably estimate accrual adjust transaction cost manage site accrual adjust periodically assessment change additional information feasibility study relate cost assessment remedial available product liability claim portion technique complete extent overall accrual actuarially determined consider potentially responsible party prps jointly factor past experience number claim report severally liable expect contribute determined estimate claim incur report individually company remediate environmental significant contingent loss accrue probable contamination result past industrial activity certain reasonably estimable site take active role identify provide legal defense cost expect incur connection cost worldwide survey initially perform loss contingency accrue probable assess site potential contamination result past reasonably estimable december company industrial activity assessment indicate physical establish reserve million solely future investigation warrant investigation perform legal defense cost relate vioxx lawsuit vioxx provide well evaluation need remedial action investigation company spend million need identify remedial action aggregate legal defense cost worldwide relate initiate estimate extent contamination site vioxx product liability lawsuit vioxx shareholder initially preinvestigation stage liability lawsuit iii vioxx foreign lawsuit vioxx potential cost remediation accrue time investigation collectively vioxx litigation fourth definitive information available quarter company record charge million course investigation andor remedial effort site increase reserve solely future legal defense cost estimate refined accrual adjust accordingly relate vioxx million december estimate related accrual continue refine reserve base certain assumption well annually estimate company believe time company believe compliance material reasonably estimate spend respect applicable environmental law regulation significant factor consider establishment expenditure remediation environmental liability ongoing review reserve vioxx legal defense cost million estimate million year management opinion liability environmental matter probable reasonably estimable accrue total merck report shareholder million million december portfolio approximate reflect equity december respectively liabilitie allocation diversification benefit asset undiscounte consider potential recovery insurer class portfolio invest party pay periods actuarial assumption base management good remediation applicable site expect occur estimate judgment reasonably possible change plus primarily year possible minus basis point discount rate assumption predict certainty outcome matter assumption hold constant estimate ultimate cost remediation management believe million favorable unfavorable impact net pension reasonably possible expenditure incur postretirement benefit cost reasonably possible change excess liability accrue exceed million plus minus basis point expect rate return aggregate management believe assumption assumption hold constant expenditure result material adverse effect estimate million favorable unfavorable impact net company financial position result operation liquidity pension postretirement benefit cost company capital resource year expect minimum pension funding requirement internal revenue code precede pension postretirement benefit plan hypothetical change discount rate expect rate return assumption impact company fund net pension postretirement benefit cost total requirement million million pension postretirement benefit plan information financial unrecognized net loss amount reflect experience reporting purpose calculate actuarial assumption differential primarily relate difference expect include discount rate plan benefit obligation actual return plan asset effect expect rate return plan asset change actuarial assumption expect return base calculate marketrelated value asset company reassesse benefit plan assumption methodology asset gainslosse result actual return regular basis pension postretirement differ company expect return recognize benefit plan discount rate evaluate annually modify reflect prevail market rate december marketrelate value asset ratably fiveyear portfolio highquality fixedincome debt instrument period total unrecognized net loss amount excess provide future cash flow need pay benefit certain threshold amortize net pension postretirement benefit cost average remain service include benefit obligation come life employee amortization total unrecognized net loss december company change discount rate company plan december pension plan discount rate company postretirement benefit plan remain expect increase net pension postretirement benefit cost approximately million annually expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit taxis income include benefit obligation pay develop company effective tax rate base pretax income expect rate return company consider longterm statutory tax rate tax planning opportunity available compound annualize return historical market datum jurisdiction company operate actual return company plan asset apply estimate effective tax rate year apply adjustment reflect recent capital market experience company quarterly operating result event reference information company develop significant unusual onetime item recognize expect forwardlooke return expectation asset category recognize company quarterly operating result weight average expect longterm rate return tax attributable item separately calculate targeted portfolio allocate investment category record time unusual onetime item expect portfolio performance reflect contribution company consider resolution prior year tax matter active management appropriate result analysis item significant judgment require determine company expect rate return company effective tax rate evaluate tax remain unchanged pension position company establish reserve despite postretirement benefit plan belief tax return position fully supportable certain target investment portfolio company position likely challenge pension postretirement benefit plan allocate succeed note financial statement equitie international equity information company adjust reserve light fixedincome investments cash change fact circumstance close tax investment portfolio equity weighting audit consistent longterm nature plan benefit tax regulation require item include tax return obligation expect annual standard deviation return different time item reflect financial target statement result effective tax rate reflect financial statement different report merck report shareholder tax return difference permanent transition election relate accounting tax effect expense deductible tax return sharebase payment award provide optional timing difference depreciation expense timing short cut method calculate historical pool windfall difference create defer tax asset liability defer benefit adoption fas company adopt tax asset generally represent item tax fas fsp effective january deduction credit tax return future year company continue use blackschole valuation company record tax benefit financial method apply modify prospective method statement company establish valuation allowance result adoption statement merck compensation defer tax asset expect future expense sharebase payment expect taxable income likely support use deduction approximately million credit defer tax liability generally represent tax expense november fasb issue fsp fsp recognize financial statement payment mean otherthantemporary impairment defer expense company application certain investment fsp address take deduction tax return recognize determination investment consider impair expense financial statement impairment temporary previously disclose october ajca measurement impairment loss accounting sign law ajca create temporary incentive consideration subsequent recognition otherthan multinational repatriate accumulate income earn temporary impairment require certain disclosure outside united states december unrealize loss recognize otherthan connection ajca company repatriate temporary impairment fsp effective begin billion note result repatriation january effect statement company company record income tax charge million financial position result operation expect taxis income relate repatriation material charge partially offset million benefit associate december sec issue interpretation decision implement certain tax planning strategy commission guidance accounting sale company change intention indefinitely reinv vaccine bioterror countermeasure federal accumulate earning earn subsequent december government placement pediatric vaccine stockpile december foreign earning billion strategic national stockpile effective beginning retain indefinitely subsidiary company january interpretation sec reinvestment provision income taxis object revenue recognition sale vaccine payable distribution earning bioterror countermeasure federal government practicable determine relate placement stockpile relate vaccine unrecognize defer income tax liability child program strategic national stockpile effect adoption interpretation company financial recently issue accounting standard position result operation expect material november fasb issue statement inventory costsan amendment arb chapter fas cautionary factor affect future result effective begin january fas annual report write report oral statement require abnormal amount idle facility expense freight time time company contain socalled handling cost waste material recognize current forwardlooking statement base period charge statement require allocation management current expectation subject risk fix production overhead base normal capacity uncertainty cause result differ materially production facility effect statement set forth statement identify company financial position result operation forwardlooke statement use word expect material expect plan estimate forecast project december fasb issue statement word similar meaning identify sharebased payment fas originally fact relate strictly historical current intend effective begin july fact statement likely address company april securities exchange commission growth strategy financial result product development product sec issue new rule delay company effective approval product potential development program date fas beginning january fas carefully consider statement require sharebased payment employee understand factor cause actual result differ expensed requisite service period base grant materially company forwardlooke statement date fair value award require unvested factor include inaccurate assumption broad portion outstanding award adoption recognize variety risk uncertainty include fair value attribution methodology know forwardlooke statement previously determine statement accounting guarantee actual future result vary materially stockbased compensation november fasb issue fasb staff position fsp mercks report shareholder company assume obligation update cash dividend pay common share forwardlooke statement carefully evaluate statement light factor include risk factor describe year companys filing securities exchange commission especially form item company annual report year end december file march common stock market price company discuss detail important factor cause actual result differ expect historic result company note factor investor igh permit private security litigation reform act low prior filing year end december reference item company annual report year end igh december understand low possible predict identify factor consequently principal market trading common stock reader consider list complete new york stock exchange nyse symbol mrk statement potential risk uncertaintie common stock market price information base historical nyse market price condense interim financial datum million share amount ale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income continue operation tax net income basic earning common share earning common share assume dilution ale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income continue operation tax net income basic earning common share earning common share assume dilution prior period amount reclassify reflect separate line item presentation restructuring cost amount include impact restructuring action note amount include impact reserve vioxx legal defense cost note amount include impact voluntary worldwide withdrawal vioxx note amount include impact net tax charge primarily associate ajca repatriation note merck report shareholder consolidate statement income merck inc subsidiary year end december millions share amount ale ost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net ncome continue operation taxis tax income ncome continue operation income discontinue operation net taxis income asic earning common share continue operation discontinue operation net income arning common share assume dilution continue operation discontinue operation net income add result round consolidated statement retain earning merck inc subsidiary year end december millions alance january income common stock dividend declare spinoff medco health alance december consolidate statement comprehensive income merck inc subsidiary year end december millions income ther comprehensive income loss net unrealized gain loss derivative net tax net income realization net unrealized gain loss investment net tax net income realization minimum pension liability net tax cumulative translation adjustment relate equity investee net tax omprehensive income accompany note integral consolidated financial statement merck report shareholder consolidated balance sheet merck inc subsidiary december million sset current asset cash cash equivalent shortterm investment account receivable inventory exclude inventory classify assetssee note prepay expense taxis otal current asset nvestment roperty plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation oodwill ther intangible net ther asset liabilitie stockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable otal current liability ongterm debt eferre income taxis noncurrent liability inority interest tockholder equity common stock cent par value authorize share issue share share paidin capital retain earning accumulate comprehensive income loss treasury stock cost share share otal stockholder equity accompany note integral consolidated financial statement merck report shareholder consolidate statement cash flow merck inc subsidiary year end december millions ash flow operating activity continue operation net income income discontinue operation net taxis ncome continue operation adjustment reconcile income continue operation net cash provide operating activity continue operation depreciation amortization defer income taxis equity income affiliate dividend distribution equity affiliate net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability cash provide operating activity continue operation ash flow invest activity continue operation capital expenditure purchase security subsidiary investment proceed sale security subsidiary investment acquisition banyu share cash provide investing activity continue operation ash flow financing activity continue operation net change shortterm borrowing proceed issuance debt payment debt redemption prefer unit subsidiary purchase treasury stock dividend pay stockholder proceed exercise stock option cash financing activity continue operation ffect exchange rate change cash cash equivalent iscontinue operation revise net cash provide medco health operating activity net cash provide medco health investing activity dividend receive medco health net intercompany settlement cash transfer cash provide discontinued operation increase decrease cash cash equivalent cash cash equivalent begin year ash cash equivalent end year accompany note integral consolidated financial statement merck report shareholder note consolidated financial statement merck inc subsidiarie million share amount fair value company consider available evidence nature operation evaluate potential impairment investment include merck global researchdriven pharmaceutical company duration extent fair value cost discover develop manufacture market broad company ability intent hold investment range innovative product improve human animal health directly joint venture company revenue recognition revenue sale product product include therapeutic preventive agent generally recognize title risk loss pass customer sell prescription treatment human disorder revenue domestic pharmaceutical sale recognize time shipment foreign subsidiary vaccine sale revenue recognize time summary accounting policy delivery recognition revenue require reasonable principle consolidation consolidated financial assurance collection sale proceed completion statement include account company performance obligation domestically sale discount subsidiary control interest maintain issue customer direct discount pointofsale controlling interest determine majority ownership indirectly intermediary wholesale purchaser know interest absence substantive thirdparty participate chargeback indirectly form rebate right case variable interest entity majority additionally sale generally limited right exposure expect loss residual return return certain condition revenue record net consolidated subsidiary merck ownership provision sale discount return outside stockholder interest show establish time sale accrual chargeback minority interest investment affiliate reflect direct reduction accounts receivable company significant influence control accrual rebate accrue expense accrue interest interest entity own equally balance relative provision include account company party share control receivable accrue current liability carry equity basis million billion respectively december foreign currency translation dollar million million respectively functional currency company foreign subsidiary december cash cash equivalent cash equivalent depreciation depreciation provide estimate comprise certain highly liquid investment original useful life asset principally straightline maturity month method tax purpose accelerate method estimate useful life primarily range year inventory substantially domestic pharmaceutical building year machinery equipment inventory value low lastin firstout lifo office furnishing cost market book tax purpose foreign pharmaceutical inventory value low firstin goodwill intangible goodwill represent firstout fifo cost market inventory consist currently excess acquisition cost fair value net asset market product certain product await regulatory business purchase goodwill assign reporting unit approval evaluate recoverability inventory company segment evaluate impairment produce preparation product launch company annual basis fair value base test consider probability revenue obtain acquire intangible record cost future sale relate inventory status amortize straightline basis estimate useful product regulatory approval process life note event circumstance warrant review company assess recoverability future investment investment classify availableforsale operation intangible undiscounted cash flow report fair value unrealize gain loss derive low appropriate asset grouping generally extent hedge report net tax accumulate subsidiary level impairment recognize operate comprehensive income investment debt security result extent carry value exceed fair value classify heldtomaturity consistent management determine base net present value intent report cost impairment loss charge estimate future cash flow income expense net otherthantemporary decline merck report shareholder research development research development grantdate fair value award requires expense incurred upfront milestone payment unvested portion outstanding award adoption party connection research development recognize fair value attribution collaboration prior regulatory approval expense methodology previously determine statement incur payment party subsequent accounting stockbase compensation regulatory approval capitalize amortize november fasb issue fasb staff position shorter remaining license product patent life fsp transition election relate accounting tax effect sharebase payment award stockbase compensation employee stockbase provide optional short cut method calculate compensation recognize intrinsic value method historical pool windfall benefit adoption fas generally employee stock option grant purchase company adopt fas fsp effective share company stock fair market value time january company continue use black grant accordingly compensation expense recognize schole valuation method apply modify company stockbase compensation plan prospective method performancebase award restrict stock unit accordance current accounting requirement option grant employee certain equity method company recognize pro forma compensation expense investee employee include retirementeligible employee effect net income earning common share vest period employee stock option company apply fair value method recognize adoption fas compensation expense employee stockbase compensation follows recognize immediately award grant retirement eligible employee period grant date year end december date retirement eligibility achieve approach know income report nonsubstantive vest period approach compensation expense net company apply nonsubstantive vest tax period approach stock option grant retirementeligible report employee effect pro forma earning share fair value method assume dilution period present provide forma net income table significant arning common share prior pro forma compensation expense option continue operation grade vest term calculate black assume dilutiona report schole model base singleoption valuation approach assume dilutionpro forma straightline method amortization earning common share company revise assumption utilize black basic report schole model determine pro forma compensation basicpro forma expense base historical datum expense assume dilutiona report determine separate expect term assumption assume dilutionpro forma vest tranche result pro forma compensation expense stock option grant january average fair value employee nonemployee prior january calculate director option grant accelerate amortization method prescribe fasb respectively fair value interpretation accounting stock appreciation right estimate blackschole optionprice model base variable stock option award plan weighted average market price grant date adoption fas effective january follow company recognize compensation expense weighted average assumption straightline method connection medco health solutions inc year end december medco health spinoff option grant medco health ividend yield employee prior february option grant riskfree interest rate february fully vested accordance volatility original term grant result pro forma expect life year compensation expense reflect accelerate vest option addition certain stock option grant december financial accounting standard medco health employee convert board fasb issue statement sharebase medco health option term amount maintain payment fas originally intend option holder position pro forma effective begin july april compensation expense option reflect securities exchange commission sec issue new rule date spinoff delay company effective date fas beginning january fas require share base payment employee expense requisite service period base merck report shareholder pretax cost restructure program legal defense cost legal defense cost expect million expect million incur connection loss contingency accrue billion end initial probable reasonably estimable phase restructing program expect use estimate consolidated financial statement substantially complete cumulative pretax cost prepare conformity accounting principle generally program expect range billion billion accept united states gaap accordingly approximately cumulative pretax cost non include certain amount base management good cash relate primarily accelerate depreciation estimate judgment estimate determine facility schedule closure item provision sale discount return million cost incur depreciable amortizable life recoverability inventory comprise million separation cost record produce preparation product launch amount restructure cost million accelerate record contingency environmental liability depreciation asset impairment cost reserve pension postretirement benefit plan million record material production assumption tax income uncertainty million record research development inherent estimate actual result differ company plan close basic research center estimate terling park united kingdom incur additional accelerate depreciation cost million record reclassification certain reclassification research development reduce prior year amount conform current year asset research center net realizable presentation value subsequent december research development perform site separation cost associate elimination voluntary product withdrawal approximately position december september company announce comprise actual headcount reduction voluntary worldwide withdrawal vioxx arthritis acute elimination contractor vacant position pain medication company decision effective estimate future termination roughly position immediately base new threeyear datum probable reasonably estimate prospective randomize placebocontrolle clinical trial december include million approve adenomatous polyp prevention vioxx separation cost million relate curtailment connection withdrawal company settlement termination charge companys pension record unfavorable adjustment net income postretirement benefit plan note million share adjustment pretax million approximately million income million million associate abandonment certain fix asset relate estimate customer return product previously long business result sell record reduction sale million restructuring action write related writeoff inventory hold company remain million reflect accelerate depreciation cost record material production expense primarily relate merck own manufacturing million relate estimate cost undertake facility worldwide preclinical site sell withdrawal product record marketing close end manufacture facility administrative expense tax benefit adjustment include action ponder end united kingdom million reflect geographical mix vioxx okazaki japan kirkland canada albany georgia return cost withdrawal adjustment danville pennsylvania preclinical site okazaki include charge future legal defense cost note menuma japan action effort reduce december million remain cost consolidate company manufacture accrue balance report accrue current research facility december buyer liabilitie million report reduction identify site closure account receivable vioxx withdrawal process anticipate complete end subject complete cost associate compliance legal obligation site withdrawal line original amount record continue operate respective closure date company future cash flow sufficient recover respective book value merck require accelerate restructure depreciation site asset write immediately site asset include manufacture november company announce phase research facility equipment global restructuring program design reduce costreduction initiative announce company cost structure increase efficiency enhance october complete end company competitiveness initial step include eliminate position company complete similar implementation new supply strategy merck program position eliminate manufacturing division intend create lean costeffective customerfocused manufacturing model year program merck plan sell close manufacture site preclinical site end eliminate approximately position companywidemerck report shareholder december result restructure action continue receive additional payment company record restructuring cost million royalty base achieve program objective million amount july merck enter agreement geron respectively million million relate corporation geron develop cancer vaccine employee severance benefit million telomerase telomerase enzyme active cancer million relate curtailment settlement termination cell maintain telomere length end charge companys pension postretirement chromosome activity allow cancer grow benefit plan note million related metastasize long period time geron receive modification term certain employee stock option upfront payment base certain development grant regulatory event receive additional payment company record restructure activity accordance royalty fas employer account postemployment sumitomo pharmaceutical ltd sumitomo benefitsan amendment fasb statement merck sign agreement june collaborate fas employer accounting settlement lurasidone atypical antipsychotic compound curtailment define benefit pension plan termination currently phase development treatment benefit fas accounting impairment schizophrenia chronic disable disposal longlive asset fas accounting severe mental illness agreement sumitomo cost associate exit disposal activity grant merck affiliate exclusive license summarize information relative employee part world japan china severance benefit accrual exclude pension korea taiwan postretirement benefit activity note follow april merck bristolmyers squibb company bm enter worldwide collaborative agreement globally develop market pargluva bmss investigational alance january oral medicine treatment type diabetes expense previously report company bms payment october fda issue approvable letter alance december pargluva request additional safety information address fully cardiovascular safety profile pargluva datum requirement cause significant delay research collaboration acquisitionsdivestiture product launch result bms merck license agreement terminate collaborative agreement pargluva merck continue strategy establish strong external right pargluva backup compound pargluva alliance complement substantial internal research return bms december capability include research collaboration license pre march company acquire aton pharma inc clinical clinical compound technology transfer aton privately hold biotechnology company focus drive nearand longterm growth merck development novel treatment cancer sign agreement disease aton clinical pipeline histone deacetylase october agensys inc agensys cancer inhibitor represent class antitumor agents potential biotechnology company merck announce formation efficacy base novel mechanism action aton lead global alliance jointly develop commercialize ags product candidate suberoylanilide hydroxamic acid know psca agensys fully human monoclonal antibody mab vorinostat extensively study treatment prostate stem cell antigen psca agreement grant cutaneous tcell lymphoma consideration acquisition merck worldwide right agspsca exclusive license consist upfront payment include contingent psca proprietary agensys target right payment base regulatory filing approval sale therapeutic diagnostic product develop product connection transaction company alliance signing agreement agensys receive record charge million acquire research upfront payment receive million associate product development milestone payment successful development acquisition date technological feasibility launch increase million multiple establish alternative future use exist charge oncology indication successfully develop approve record research development expense addition royaltie worldwide sale remain net asset acquire transaction september foxhollow technologies inc material aton development stage company foxhollow merck announce formation novel commence plan principal operation pharmacogenomic collaboration collaboration focus transaction account acquisition asset analyze atherosclerotic plaque remove patient business combination goodwill artery mean identify new biomarker record aton result operation atherosclerotic disease progression use development include company acquisition date cardiovascular compound mercks pipeline february merck lundbeck lundbeck agreement include research collaboration enter agreement exclusive development year foxhollow receive upfront payment commercialization gaboxadol compound collaboration treatment sleep disorder term agreement lundbeck receive initial payment million dur merck report shareholder ing term agreement receive follow summary asset liability million additional milestone payment future discontinued operation spin company record upfront payment research development expense merck fund majority august remain development activity june merck sset lundbeck extend agreement exclusive ash cash equivalent development commercialization gaboxadol japan current asset company wholly own subsidiary property plant equipment net msd japan ltd launch tender offer acquire goodwill remain common share banyu intangible net pharmaceutical ltd banyu asset aggregate purchase price approximately billion substantially share acquire iabilitie march merck complete acquisition banyu urrent liability ownership banyu strengthen merck position japan longterm debt world second large pharmaceutical market defer income taxis company acquisition banyu share account purchase method pro forma information provide impact transaction asset transfer material effect company consolidated result operation aggregate purchase price financial instrument allocate base fair value portion asset foreign currency risk management liability acquire allocation aggregate dollar functional currency purchase price result reversal billion company foreign subsidiary significant portion minority interest liability recognition million company revenue denominate foreign currency intangible million goodwill million merck relie sustain cash flow generate foreign defer income tax liability million net source support longterm commitment dollar asset principally property plant equipment base research development extent dollar intangible include million inline product right value cash flow diminish result strengthen year weight average useful life dollar company ability fund research dollar million represent year life tradename base strategic initiative consistent level connection transaction company incur impair company establish revenue hedging charge million acquire research record balance sheet risk management program protect research development expense associate product volatility future foreign currency cash flow change development acquisition date technological fair value cause volatility foreign exchange rate feasibility establish alternative future objective revenue hedging program reduce use exist potential longerterm unfavorable change foreign august merck complete spinoff exchange decrease dollar value future cash medco health income medco health present flow derive foreign currency denominate sale separately discontinue operation prior spinoff primarily euro japanese yen achieve merck receive billion dividend medco health objective company partially hedge anticipate merck pay million settlement net party sale expect occur planning cycle intercompany payable medco health addition date typically year future spinoff million cash cash equivalent company layer hedge time increase portion include net asset medco health sale hedge get close expect date spin statement cash flow restate transaction probable hedge transaction separately disclose operate investing portion occur portion sale hedge base cash flow attributable discontinued operation assessment costbenefit profile consider natural amount previously report combined basis offset exposure revenue exchange rate volatility summarize financial information discontinue correlation cost hedging instrument operation follows hedge anticipate sale specify component portfolio similarly denominate foreign currencybase sale year end december transaction respond hedged risk otal net revenue manner merck manage anticipate transaction income taxis exposure principally purchase local currency option taxis income provide company right obligation income net taxis sell foreign currency future predetermine price dollar strengthen relative currency include operation august hedge anticipate sale total change merck report shareholder option cash flow fully offset decline expect fair value forward exchange contract report future dollar cash flow hedge foreign currency follow balance sheet line item account receiv sale conversely dollar weaken option able current portion gain position asset non value reduce zero company benefit current portion gain position accrue current increase value anticipate foreign currency cash liability current portion loss position defer income flow taxis noncurrent liability noncurrent portion loss designate hedge relationship base total position change option cash flow accordingly entire fair value change option defer accumulate interest rate risk management comprehensive income aoci reclassify sale company use interest rate swap contract certain hedge anticipate revenue recognize invest borrowing transaction manage net expo hedge relationship perfectly effective hedge sure interest rate change reduce overall cost ineffectiveness record fair value currency option borrowing company use leveraged swap report account receivable asset general leverage investment activity primary objective balance sheet risk principal capital risk management program protect dollar value december company party foreign currency denominate net monetary asset payfloate receivefixe interest rate swap contract desig effect volatility foreign exchange occur prior nate fair value hedge fixedrate note mature conversion dollar merck principally utilize respectively notional amount forward exchange contract enable company buy swap match hedge fixedrate sell foreign currency future fix exchange rate note million million million economically offset consequence change respectively swap effectively convert fixedrate foreign exchange dollar cash flow obligation floatingrate instrument fair value change derive net asset merck routinely enter note fully offset interest expense fair value contract fully offset effect exchange exposure change swap contract fair value denominate develop country currency primarily contract report account receivable asset euro japanese yen exposure develop country accrue current liability defer income taxis currency company enter forward contract noncurrent liability limited basis deem economical base costbenefit analysis consider fair value financial instrument magnitude exposure volatility exchange rate summarize carry value fair value cost hedge instrument company company financial instrument december minimize effect exchange monetary asset fair value estimate base market price liability manage operating activity net asset available dealer quote position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance carry fair carry fair sheet date effect change spot rate report value value value value income expense net forward contract sset designate hedge mark market ash cash income expense net accordingly fair value change equivalent forward contract help mitigate change value shortterm remeasure asset liability attributable change investment foreign currency exchange rate extent longterm spotforward difference difference significant investment shortterm nature contract typically purchase currency average maturity inception year option company periodically use forward contract hedge forward exchange change fair value certain foreign currency contract denominate availableforsale security attributable interest rate swap fluctuation foreign currency exchange rate change iabilitie fair value hedge security fluctuation oan payable spot rate offset income expense net fair current portion value change forward contract attributable spot rate longterm debt fluctuation hedge ineffectiveness material longterm debt change contract fair value write currency spotforward difference exclude designate option hedge relationship recognize income expense forward exchange net amount significant year end contract december currency swap outstanding december merck report shareholder connection american job creation act concentration credit risk ajca company repatriate billion ongoing control procedure company moni note december billion ajca tor concentration credit risk associate corporate repatriation invest fully collateralize overnight issuer security financial institution repurchase agreement include shortterm conduct business credit risk minimal credit exposure investment consolidate balance sheet limit establish avoid concentration single summary december carry value fair issuer institution customer represent value company investment gross unrealized aggregate approximately onethird company account gain loss companys availableforsale receivable december company monitor investment record net tax aoci follow creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral carry fair gross unrealized security support credit sale value value gain loss vailableforsale inventory repurchase inventory december consist agreement corporate note bond inished good commercial paper raw material work process municipal security supply government agency security otal approximate current cost debt security reduction lifo cost equity security otal availableforsale ecognize heldtomaturity inventory security asset inventory value lifo method comprise approximately inventory december carry fair gross unrealize respectively amount recognize value value gain loss asset comprise entirely raw material work vailableforsale process inventory include inventory produce corporate note preparation product launch principally vaccine bond inventory product principally vaccine government arcoxia expect sell year agency security intangible commercial paper intangible december consist municipal security foreign government bond atent product right debt security equity security otal acquire cost otal availableforsale heldtomaturity atent product right security availableforsale debt security mature year otal accumulate amortization total billion december remain aggregate amortization expense substantially debt security million mature year record material production expense million million million estimate aggregate amortization expense year follow million million million million million merck report shareholder partnership return record equity income affiliate return include priority return provide joint venture equity method affiliate partnership agreement variable return base company scheringplough corporation sale certain astra usa inc products scheringplough enter agreement create separate preferential return represent merck share undistribute equallyowne partnership develop market azlp gaap earning return aggregate united states new prescription medicine cholesterol million million million management respiratory therapeutic area respectively result reflect low cholesterolmanagement partnership agreement preferential return primarily result impact expand include country world exclude generic competition prilosec astrazeneca merger japan ezetimibe new class trigger partial redemption mercks limited partnership cholesterollowere agent launch united states interest redemption azlp distribute zetia market ezetrol outside united states kbi base primarily multiple merck report merckscheringplough partnership global average annual variable return derive sale sale zetia total billion billion astra usa inc product year prior million july combination redemption limited partner share agree value product contain active ingredient zetia conjunction restructure payment zocor approve united states vytorin million defer astra purchase option market inegy outside united states vytorin asset option buy merck interest kbi product approve country outside united states exclude gastrointestinal medicine nexium prilosec global sales vytorin billion asset option exercisable exercise price million result company equal net present value march interest merckscheringplough partnership record project future pretax revenue receive equity income affiliate income company kbi product appraise value merck million million loss right require astra purchase interest million appraise value addition company merck enter agreement astra grant astra option buy merck common stock interest astra develop market astra product royalty kbi exercisable year astra purchase merck bear license company total sale astra interest kbi product exercise option product reach level trigger step astra provide year combine establishment joint venture business carry astra annual sale product fall minimum merck inc ami merck astra own provide case long merck option share joint venture form develop astrazenecas option exercise market astra new prescription medicine exercise price base net present value united states include prilosec class estimate future net sale nexium prilosec medication know proton pump inhibitor slow determined time exercise production acid cell stomach lining astrazeneca merger constitute trigger event merck astra complete restructure kbi restructuring agreement result ownership operation joint venture merger exchange merck relinquishment right company acquire astras interest ami rename kbi inc future astra product exist pende patent kbi contribute kbis operating asset new time merger astra pay million limited partnership astra pharmaceutical advance payment subject trueup calculation partnership exchange limited partner interest require repayment portion astra contribute net asset wholly own subsidiary trueup directly dependent fair astra usa inc partnership exchange market value astra product right retain general partner interest partnership rename company accordingly recognition contingent income astrazeneca azlp astras merger defer realizable zeneca group plc astrazeneca merger determinable anticipate prior exclusive distributor product kbi retain provision kbi restructuring agreement right trigger event occur sum limited maintain limited partner interest azlp partner share agree value appraise value merck consent protective right intend preserve trueup guarantee minimum billion business economic interest include restriction distribution limited partner share agree value power general partner certain distribution payment trueup occur disposition furthermore limit event default astrazenecas purchase merck interest kbi product additional right grant company include contingent exercise merck option power direct action remove replace astrazenecas option payment partnership chief executive officer chief financial officer appraise value occur merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain merck report shareholder merck rhnepoulenc sanofi million million respectively longdate note aventis combined animal health poultry subject repayment option holder genetic business form merial limited merial fully annual basis million note annual interest rate integrate animal health company standalone joint reset final maturity annual basis venture equally own party merial provide note repurchase holder option comprehensive range pharmaceutical vaccine remarkete agent remarkete redeem enhance health wellbeing performance wide company loan payable december range animal specie merial sale billion include million fixedrate note billion billion billion fix rate note respectively merck pasteur mrieux connaught weight average interest rate borrowing sanofi pasteur establish equallyowne joint december respectively venture market vaccines europe collaborate longterm debt december consist development combination vaccine distribution europe joint venture vaccine sale million million million astra note merck form joint venture johnson notes johnson develop market broad range nonprescrip note tion medicine consumer own venture debenture expand europe canada debenture march merck sell equity stake european note joint venture johnson johnson million variablerate borrowing record million gain income expense net debenture note merck continue benefit royalty note certain product regain right potential future product switch prescription overthe counter status europe sale product market joint venture include sale european joint venture company party interest rate swap contract march million effectively convert fixedrate million million note floatingrate instrument note investment affiliate account equity present table december method include joint venture total billion consist primarily million borrowing december billion december variable rate average respectively amount report asset dividend borrowings million subject repayment option distribution receive affiliate billion holder begin million subject million million repayment option holder begin summarize information affiliate follow year include foreign borrowing vary rate year end december aggregate maturity longterm debt ale year follow million material production cost million billion million expense net million income taxis rental expense company operating lease net ecember sublease income million minimum urrent asset aggregate rental commitment noncancellable lease noncurrent asset follow million million current liability million million million noncurrent liability million company significant capital lease loan payable longterm debt contingency environmental liability commitment company involve claim legal loan payable december include proceeding nature consider normal business billion million respectively commercial include product liability intellectual property commercial paper borrowing commercial paper borrowing december litigation additional matter antitrust action include billion issue foreign subsidiary company record accrual contingency billion commercial paper borrowing facility probable liability incur establish october provide funding portion reasonably estimate accrual adjust periodically company repatriation connection ajca assessment change additional information note loan payable december include merck report shareholder available product liability claim portion judge fallon indicate intends try series overall accrual actuarially determined consider case period november factor past experience number claim report follow category heart attack short term use heart estimate claim incur report individually attack long term use iii stroke cardiovascular significant contingent loss accrue probable injury involve prescription write april reasonably estimable legal defense cost expect labeling vioxx revise include result vigor incur connection loss contingency accrue trial probable reasonably estimable november december case bring evelyn company decision obtain insurance coverage irvin plunkett behalf late husband richard irvin dependent market condition include cost die apparent heart attack try houston availability exist time decision texas plaintiff allege irvin take vioxx approximately result number factor product liability insurance month action fall category heart available cost increase attack short term use deliberate onehalf significantly company evaluate risk day court find jury deadlocke declare determined cost obtain product liability insurance mistrial federal court rule require unanimous verdict outweighs likely benefit coverage available retrial case commence february new insurance certain product liabilities orleans louisiana february jury return verdict effective august include liability product favor merck count sell date company continue evaluate schedule mdl trial diaz merck case insurance need cost availability benefit plaintiff claim heart attack long term use product liability insurance future schedule addition diaz case garza case discuss vioxx product liability lawsuit vioxx litigation currently schedule trial product liability lawsuit previously disclose august trial state previously disclose federal state product liability court texas jury ernst merck reach verdict lawsuit involve individual claim putative class favor plaintiff purport award total action file company respect million compensatory punitive damage vioxx december company texas law maximum award serve aware name defendant plaintiff cap approximately million company approximately lawsuit include approximately intend appeal verdict completion posttrial plaintiff group allege personal injury result proceeding trial court company believe use vioxx lawsuit approximately strong point raise appeal hopeful appeal lawsuit represent approximately plaintiff group process correct verdict company believe slate federal mdl discuss potential unfavorable outcome probable approximately lawsuit represent approximately establish reserve respect verdict plaintiff group include coordinate proceeding november case frederick mary new jersey superior court judge carol higbee jackson humeston merck inc superior court new certain lawsuit include allegation jersey law division atlantic county jury return verdict gastrointestinal bleed cardiovascular event thrombotic favor merck count case second vioxx event kidney damage company name personal injury case trial humeston year old defendant approximately putative class action united states postal employee idaho allege allege personal injury seek medical monitoring suffer heart attack september result take result putative class member use vioxx vioxx seek compensatory punitive damage jury disgorgement certain profit common law unjust find vote merck fail provide enrichment theory andor iii remedy state adequate warning prescribing physicians association consumer fraud fair business practice statute include vioxx increase risk cardiovascular recover cost vioxx purchase individual event prior humeston heart attack jury thirdparty payor union health plan action unanimously find merck violate new jersey discuss paragraph collectively refer consumer fraud act marketing drug prescribing vioxx product liability lawsuit action file physicians state courts california texas new jersey trial garza heart clinic evans posada merck philadelphia pennsylvania respectively inc begin january judicial transfer single judge state coordinate district court starr county texas company believe proceeding addition february judicial evidence case vioxx cause heart panel multidistrict litigation jpml transfer attack leonel garza garza die heart attack vioxx product liability lawsuit pende federal court april follow year cardiovascular disease nationwide multidistrict litigation mdl prior heart attack approximately coordinate pretrial proceeding mdl transfer united states district court eastern district louisiana district judge eldon fallon merck report shareholder consolidate amend class action complaint supersede month death company maintain prior complaint case complaint plaintiff garza give oneweek supply vioxx request certification class purchaser company stock sample pain october complaint merck enter tolling agreement tolling allege defendant false misleading agreement mdl plaintiff steer committee statement vioxx violation section establishe procedure halt run statute securities exchange act seek limitation toll certain category claim allegedly unspecified compensatory damage cost suit arise use vioxx nonnew jersey citizen include attorney fee complaint assert claim tolling agreement apply individual file section security exchange act lawsuit eventually file lawsuit certain defendant relate sale merck stock claimant seek toll claim allege injury addition complaint include allegation section result thrombotic cardiovascular event result security act certain defendant myocardial infarction ischemic stroke tolling incomplete misleading statement registration agreement provide counsel additional time evaluate statement certain prospectus file connection potential claim tolling agreement requires toll merck stock investment plan dividend reinvestment plan claim file federal court december defendant file motion dismiss complaint approximately claimant enter tolling pende agreement previously disclose august complaint lawsuit file oregon state court state oregon previously disclose july new jersey state oregon state treasurer behalf oregon public employee trial court certify nationwide class thirdparty payor retirement fund company certain current union health insurance plan pay officer director complaint bring vioxx plan member insured oregon security law allege plaintiff suffer name plaintiff case seek recovery certain damage connection purchase merck common vioxx purchase cost plus penalty base allegation stock artificially inflate price company allege purport class member pay vioxx violation law relate disclosure vioxx know product allege risk company remove lawsuit district court merck believe class improperly certify trial district oregon plaintiff move remand case court rule procedural address merit state court motion grant plaintiff allegation company intend defend previously disclose number shareholder derivative vigorously new jersey state superior court appellate action file federal court new jersey division accept merck appeal class certification superior court naming company nominal defendant order expedite basis certain member board past present previously report company name certain executive officer defendant complaint arise defendant separate lawsuit bring attorney substantially factual allegation general louisiana mississippi texas attorney vioxx security lawsuit derivative suit general alaska recently file lawsuit purportedly bring assert right company assert action allege company misrepresent safety claim board member officer breach vioxx seek recovery cost vioxx purchase fiduciary duty waste corporate asset unjust enrichment reimburse state agency reimbursement abuse control gross mismanagement action sum pay state agency medical service discuss paragraph collectively refer treatment person injure vioxx iii damage vioxx derivative lawsuit jpml transfer vioxx common law theory andor remedy derivative lawsuit pende federal court shareholder state statutory theory include state mdl judge chesler consolidated vioxx derivative consumer fraud andor fair business practice medicaid lawsuit purpose june federal fraud statute include civil penalty derivative plaintiff file verify consolidated shareholder derivative complaint supersede prior complaint shareholder lawsuit case defendant file motion dismiss complaint previously disclose addition vioxx product pende addition vioxx derivative lawsuit liability lawsuit company current pende new jersey superior court consolidate officer director company defendant transfer judge higbee atlantic county april number putative class action individual lawsuit state plaintiff file supersede verify consolidate file removed federal court shareholder amend shareholder derivative complaint january federal security law vioxx security lawsuit aii shareholder derivative case dismiss transfer jpml relate prejudice case dismiss court lawsuit discuss united states district court grant defendant motion stay case court order district new jersey district judge stanley permit plaintiff refile complaint consolidated chesler inclusion nationwide mdl coordinated federal shareholder derivative case resolve pretrial proceeding shareholder mdl judge chesler consolidated vioxx security lawsuit purpose june plaintiffs vioxx security lawsuit file fourth merck report shareholder previously disclose october insurer availability insurance individual shareholder demand board coverage likely additional dispute legal action raymond gilmartin time company believe insurance coverage chairman president chief executive officer respect vioxx lawsuit adequate cover individual allegedly cause damage company defense cost loss respect allegedly improper marketing vioxx previously disclose company upperlevel excess response demand letter board director insurer provide excess insurance potentially applicable determined november meeting vioxx lawsuit commence arbitration board shareholder request seek thing cancel policy void consideration remain consideration obligation policy raise addition previously disclose number coverage issue respect vioxx lawsuit second putative class action file arbitration company upperlevel excess company certain current officer insurer commence merck intend contest director company federal court vioxx vigorously insurer claim attempt enforce erisa lawsuit vioxx security right applicable insurance policy amount actually lawsuit vioxx derivative lawsuit vioxx recover policy discuss section shareholder lawsuit behalf certain amount specify precede paragraph company current employee participant certain company retirement plan investigation assert claim employee retirement income previously disclose november company security act erisa lawsuit similar advise staff sec commencing allegation allegation contain vioxx informal inquiry concern vioxx january security lawsuit claim defendant company announce receive notice sec issue breach duty plan fiduciarie formal notice investigation company receive jpml transfer vioxx erisa lawsuit subpoena department justice doj shareholder mdl judge chesler consolidate request information relate company research vioxx erisa lawsuit purpose consolidated marketing selling activity respect vioxx federal amend complaint file vioxx erisa lawsuit health care investigation criminal statute august defendant file motion ongoing investigation certain congressional committee dismiss complaint pende previously disclose company subsidiary notify medicine healthcare product regulatory international lawsuit agency united kingdom mhra investigation previously disclose addition lawsuit mhra compliance company european discuss company name union adverse experience reporting requirement defendant litigation relate vioxx country connection vioxx addition previously disclose collectively vioxx foreign lawsuit europe investigation conduct local authority certain canada brazil australia turkey israel cities europe order determine criminal charge bring concern vioxx company additional lawsuit cooperate governmental entity respective base medium report source company investigation vioxx investigation company anticipate additional vioxx product liability lawsuit predict outcome inquiry result vioxx shareholder lawsuit vioxx foreign lawsuit potential civil andor criminal disposition collectively vioxx lawsuit file previously disclose company receive civil andor certain current officer investigative demand group attorney general director future states district columbia investigate company violate state consumer protection law insurance marketing vioxx company cooperate attorney previously disclose company product liability general respond civil investigative demand insurance claim bring vioxx product liability lawsuit state upper limit approximately reserve million deductible coinsurance company currently anticipate number vioxx insurance provide coverage legal defense cost product liability lawsuit try company potential damage amount predict timing trial respect vioxx incur connection vioxx product liability shareholder lawsuit company believe lawsuit company believe insurance meritorious defense vioxx lawsuit vigorously coverage extend additional vioxx product liability defend view inherent difficulty predict lawsuit file future company outcome litigation particularly director officer insurance coverage applicable claimant claimant seek indeterminate damage vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million additional insurance coverage claim available upperlevel excess policy provide coverage avariety risk dispute certain merck report shareholder company unable predict outcome expand number manufacturer include matter time reasonably estimate like company defendant prior possible loss range loss respect vioxx pende case court grant company lawsuit company establish reserve motion dismiss consolidated class action dismiss potential liability relate vioxx lawsuit vioxx company class action case subsequent investigation collectively vioxx litigation company dismissal plaintiff file amend legal defense cost expect incur connection consolidate class action complaint loss contingency accrue probable company defendant company reasonably estimable december company pharmaceutical manufacturer defendant similar establish reserve million solely future complaint pende federal state court bring individually legal defense cost relate vioxx litigation number county state new york company company spend million aggregate defendant await final rule legal defense cost worldwide relate vioxx product motion dismiss suffolk county case liability lawsuit vioxx shareholder lawsuit iii new york county case file addition vioxx foreign lawsuit vioxx investigation december company defendant state collectively vioxx litigation fourth quarter case bring attorney general kentucky illinois company record charge million increase alabama wisconsin mississippi arizona reserve solely future legal defense cost relate vigorously defend company receive vioxx litigation million december letter inquiry attorney general idaho reserve base certain assumption well previously disclose company name estimate company believe defendant antitrust case federal court minnesota time reasonably estimate spend state court california allege unlawful conspiracy significant factor consider establishment different set pharmaceutical manufacturer protect ongoing review reserve vioxx legal defense high price united states impede importation cost follow actual cost incur united states lowerpriced pharmaceuticals canada company time development company court dismiss federal claim minnesota case legal defense strategy structure light scope prejudice plaintiff file notice appeal vioxx litigation number case bring state claim action dismiss prejudice company cost outcome complete trial previously disclose suit federal court alabama anticipate timing progression relate cost pretrial provider health service needy patient allege activity trial vioxx product liability lawsuit pharmaceutical company overcharge plaintiff class event schedule trial expect occur similarly situate pharmaceutical purchase inherent inability plaintiff program establish section predict ultimate outcome trial limit public health service act company company ability reasonably estimate legal cost defendant file motion dismiss complaint numerous end company continue monitor ground recently deny court legal defense cost review adequacy previously disclose january doj notify associate reserve unfavorable outcome vioxx federal court new orleans louisiana go litigation material adverse effect intervene time pende federal false claim act case company financial position liquidity result file seal december operation company court issue order unseal complaint file physician louisiana order commercial litigation complaint serve complaint allege beginning company name number company discount pepcid certain louisiana hospital antitrust suit certain certify class action lead increase cost medicaid dismiss institute nation retail pharmacy amend complaint file seal case consumer state company settle federal administratively closed court seal lift class action represent single large group state louisiana file amend complaint claim settle substantially remain case incorporate allegation contain seal amend satisfactory term remain case complaint allegation contain seal amend inactive year company engage complaint unknown conspiracy admission wrongdoing april company name qui tam lawsuit include settlement agreement nevada false claim act suit previously disclose company join nevada attorney general intervene allege ongoing litigation allege manipulation pharmaceutical company inappropriately offer nominal pricing manufacturer average wholesale price awp marketing pricing inducement certain customer calculation determine public fail comply obligation medicaid good price private sector reimbursement level jpml scheme relate arrangement company order transfer consolidation pende federal vigorously defend lawsuit awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action merck report shareholder tienam product italy prior expiry spc governmental proceeding november italian administrative court deny previously disclose company receive company appeal ica order proceeding subpoena doj connection investigation ica ongoing company marketing selling activity include nominal pricing program sample company vaccine litigation report receive civil investigative demand previously disclose company party claim bring cid attorney general texas consumer protection act united companys marketing selling activity relate texas kingdom allege certain child suffer variety previously disclose company receive cid condition result vaccinate bivalent attorney general texas ask additional vaccine measle rubella andor trivalent vaccine information company marketing selling measle mump rubella include company mmr activity relate texas include respect certain condition include autism inflammatory bowel nominal pricing program sample april disease epilepsy encephalitis encephalopathy guiltainbarr company receive subpoena office inspector syndrome transverse myelitis claimants general district columbia connection proceeding company knowledge intend investigation company interaction physician proceed company company vigorously district columbia maryland virginia defend lawsuit november company receive letter request previously disclose company party doj connection investigation company individual class action product liability lawsuit claim pricing pepcid september company receive united states involve pediatric vaccine hepatitis subpoena illinois attorney general subpoena vaccine contain thimerosal preservative seek information relate repackage prescription drug vaccine merck distribute thimerosalcontaining previously disclose company receive letter pediatric vaccine united states fall doj advise existence qui tam december approximately active complaint allege company violate certain rule thimerosal relate lawsuit approximately plaintiff relate calculation good price federal pricing defendant include vaccine manufacturer benchmark calculation certain affect produce pediatric vaccine contain thimerosal company medicaid rebate obligation manufacturer thimerosal action plaintiff allege company cooperate thing suffer neurological injury investigation company predict outcome result exposure thimerosal pediatric vaccine investigation possible unfavorable state court case federal district court case outcome material adverse effect schedule trial case company financial position liquidity result dismiss case set trial dismiss operation addition time time federal state certain dismissal appeal company foreign regulator authority seek information vigorously defend lawsuit possible practice pharmaceutical industry company unfavorable outcome material adverse effect business practice inquiry investigation companys financial position liquidity result discuss section feasible predict operation outcome inquiry company successful case february italian antitrust authority type dismiss stay ground action adopt measure commence formal investigation prohibit national childhood vaccine injury act merck sharp dohme italia spa msd italy vaccine act vaccine act prohibit person file company article italian competition law maintain civil action state federal court seek article ascertain company msd italy damage vaccine manufacturer vaccinerelate committed abuse dominant position virtue injury petition file united states court company refusal grant acs dobfar spa dobfar federal claim hereinafter vaccine court italian company voluntary license pursuant domestic vaccine act file civil action vaccine legislation pass permit dobfar manufacture manufacturer petitioner pursue tienam imipenem cilastatin italy sale outside italy petition conclusion vaccine court timely file country patent protection applicable election proceed civil action lieu accept domestic rule expired exist company vaccine court adjudication petition timely exercise supplementary protection certificate spc right withdraw petition prior vaccine court adjudication provide company certain right respect accordance certain statutorily prescribe time period manufacture sale tienam italy expire company aware numerous case pende january hear italian antitrust authority vaccine court involve allegation thimerosalcontaine hold june italian vaccines andor mmr vaccine cause autism spectrum antitrust authority ica issue order impose interim disorder case refer precede paragraph measure require company grant license dismiss bring plaintiff manufacture tienam italy pursuant icas order license grant dobfar limited right manufacture build supply stock tienam allow dobfar export tienam outside italy sell merck report shareholder claim timely withdrawal vaccine regulatory authority datum weekly alendronate court petition company party vaccine reference company seek approval generic weekly court proceeding petition bring alendronate product company file leave appeal department health human service judgment swedish administration court affirm grant swedish regulatory authority approval generic weekly patent litigation alendronate product reference company datum time time generic manufacturers pharmaceutical weekly alendronate approval company file product file abbreviate new drug application anda similar case country fda seek market generic form previously announce company july company product prior expiration relevant patent opposition division european patent office render own company generic pharmaceutical oral decision revoke company patent europe manufacturer submit andas fda seeking cover onceweekly administration alendronate market united states generic form fosamax august write opinion issue confirm prilosec propecia trusopt cosopt prior expiration oral decision revoking company patent september company astrazenecas case prilosec company file appeal decision decision nexium patent concern product generic appeal expect company defend company anda generally include allegation non alendronate weekly product major european market infringement invalidity unenforceability patent base patent generic manufacturer receive fda approval market october action australia challenge generic form prilosec company file patent validity company australian patent onceweekly infringement suit federal court company file administration alendronate patent find invalid andas generic alendronate fosamax finasteride company appeal decision proscarpropecia dorzolamide trusopt addition previously disclose japan proceeding dorzolamidetimolol cosopt astrazeneca file challenge validity company company file patent infringement suit federal court japanese patent onceweekly administration company file andas generic omeprazole alendronate esomeprazole similar patent challenge exist certain january company sue hitech pharmacal foreign jurisdiction company intend vigorously inc hitech amityville new york patent defend patent believe valid infringement response hitechs application fda infringement generic company attempt market seek approval generic version merck ophthalmic product prior expiration date patent drug trusopt cosopt treat elevated litigation assurance outcome intraocular pressure people ocular hypertension adverse result significantly shorten period glaucoma lawsuit merck sue enforce patent exclusivity product cover active ingredient dorzolamide present previously disclose january trusopt cosopt merck elect enforce court appeal federal circuit washington patent list fda cover combination find company patent claim onceweekly dorzolamide timolol active ingredient cosopt administration fosamax invalid company lawsuit automatically stay fda approval hitech exhausted option appeal decision base anda month adverse court decision court appeal decision fosamax lose market whichever occur early patent cover dorzolamide exclusivity united states february provide exclusivity trusopt cosopt october company expect significant decline fosamax sale include month pediatric exclusivity time time company expect sale product decline federal court canada trial division case omeprazole trial court united states issue decision refuse bar approval generic alen render opinion october uphold validity dronate ground merck patent weekly alen company astrazenecas patent cover stabilize dronate likely invalid decision appeal formulation omeprazole rule defendant generic alendronate launch canada omeprazole product infringe patent june july merck sue federal court defendant product find infringe formulation canada apotex seek damage lose sale patent december court appeal generic weekly alendronate patent proceed federal circuit affirm decision trial court january high court justice england respect company patent infringement claim wale hold patent company protect certain generic manufacturer omeprazole product trial alendronate daily weekly product invalid schedule march united kingdom november court appeal company astrazeneca receive notice england wale affirm rule high court october ranbaxy laboratory limit ranbaxy justice england wale file anda esomeprazole magnesium anda contain european country permit company seek approval paragraph challenge patent nexium generic product reference datum innovative product november company astrazeneca sue certain circumstance datum exclusivity regulation ranbaxy united states district court new jersey high court justice affirm decision accordingly fda merck report shareholder certain plaintiff counsel file settlement agreement approval ranbaxys anda stay month federal district court new york case commence april adverse court decision whichever number plaintiff include participant number occur early pharmaceutical benefit plan medco health case finasteride anda file seek pharmacy benefit manager trustee plan approval generic version propecia allege consolidated medco health company agree invalidity company patent company file propose settlement order avoid significant cost patent infringement lawsuit district court delaware distraction prolong litigation propose class september trial schedule june settlement agree plaintiff case europe company aware company file medco health company seek registration generic losartan active ingredient propose settlement company medco health cozaar company patent right losartan agree pay total million medco health license dupont nemour company dupont agree modify certain business practice continue certain company dupont file patent infringement specify business practice period year proceeding company portugal financial compensation intend benefit member settlement class include erisa plan medco litigation health administer pharmacy benefit time july merck serve shareholder december district court hold hearing hear derivative suit file new jersey superior court objection fairness propose settlement hunterdon county company certain current approve settlement determine officer director lawsuit seeks recover number class member plan properly elect cancel compensation award company executive participate settlement settlement final officer assert claim breach fiduciary appeal resolve certain class member duty waste unjust enrichment plan indicate participate november individual shareholder deliver settlement case initiate plan letter board allege company sustain individual remain pende southern district new york damage company adoption change plaintiff case assert claim base erisa control separation benefit plan cic plan federal state law november shareholder demand similar claim assert settle class board legal action board current member gruer case company medco health member allegedly cause damage company name defendant case respect adoption cic plan response notice appeal file appellate court demand letter independent member board hear oral argument december determine november board meeting appellate court issue decision vacate district court board shareholder request judgment remand case district court allow consideration remain consideration district court resolve certain jurisdictional issue previously disclose july united states district court schedule hearing february district court district new jersey grant motion address issue company medco health solutions inc medco spinoff medco health medco health assume health certain officer director dismiss substantially liability exposure matter discuss purport class action complaint involve claim relate forego paragraph case company revenue recognition practice retail defend medco health copayment pay individual medco health legal proceeding principally product provide pharmaceutical benefit allegation liability intellectual property suit involve company complaint dismiss prejudice august pende feasible predict outcome court grant company motion proceeding proceeding discuss note dismiss prejudice relate shareholder derivative action opinion company proceeding plaintiff action appeal decision adequately cover insurance cover december court appeal ultimately result liability material adverse circuit uphold district court decision dismiss class effect financial position liquidity result operation action complaint separate decision issue day company proceeding separate court appeal uphold district court assessment provide note decision dismiss shareholder derivative suit send issue company board director environmental matter properly refuse shareholder demand relate company party number proceeding bring company treatment retail copayment district comprehensive environmental response court reconsideration different legal standard compensation liability act commonly know superfund previously disclose prior spinoff medco legitimate claim contribution assert liability health company medco health agree settle initially accrue base estimate transaction cost class action basis series lawsuit assert violation erisa gruer case company medco health merck report shareholder manage site accrual adjust feasibility study december respectively liabilitie relate cost assessment remedial technique undiscounte consider potential recovery insurer complete extent potentially party pay period responsible party prps jointly severally remediation applicable site expect occur liable expect contribute determine primarily year possible company remediate environmental predict certainty outcome matter contamination result past industrial activity certain ultimate cost remediation management believe site take active role identify provide reasonably possible expenditure incur cost worldwide survey initially perform excess liability accrue exceed million assess site potential contamination result past aggregate management believe industrial activity assessment indicate physical expenditure result material adverse effect investigation warrant investigation companys financial position result operation liquidity perform provide well evaluation need capital resource year remedial action need identify remedial action initiate estimate extent prefer stock subsidiary company contamination site initially pre december company redeem variablerate investigation stage liability potential cost preferred unit subsidiary billion par value plus remediation accrue time definitive accrue dividend prefer security hold information available course subsidiary level previously include minority investigation andor remedial effort site estimate interest consolidate financial statement refine accrual adjust accordingly connection restructuring ami note estimate related accrual continue refine annually company assume billion par value prefer stock previously disclose december virginia obligation dividend rate annum carry department environmental quality vadeq issue kbi include minority interest small portion notice violation company elkton virginia facility prefer stock carry kbi convertible kbi common air permit limit exceedance report facility result share prefer security convertible performance testing process train company common share include company settle matter vadeq agree common share issuable purpose compute earning million capital improvement site pay common share assume dilution note vadeq fine iii perform supplemental environmental project stockholder equity december company settle claim paidin capital increase million bring new jersey department environmental decrease million increase protection allege damage natural resource million change primarily reflect impact new jersey merck remediation site settlement share issue exercise stock option relate income company agree pay million donate acre land tax benefit issuance restrict share adjacent rahway river fund restoration summary treasury stock transaction share million project passaic river watershe groundwater follow contamination find company site management opinion liability environmental matter probable reasonably estimable accrue total million million share cost share cost share cost alance jan purchases issuance alance dec issue primarily stock option plan merck report shareholder december million share number outstanding option increase million preferred stock par value authorize average exercise price decrease approximately issue addition certain stock option grant medco health employee convert medco health option term amount maintain option stockbase compensation plan holder position company stockbase compensation plan summarize information relative company stock employee nonemployee director employee option plan option thousand follow certain company equity method investee grant option purchase share company common number average stock fair market value time grant option price plan approve company shareholder option utstande december grant begin generally vest ratably grant year grant prior generally vest year exercise option expire year date grant subject forfeit converted term applicable award medco health spinoff adjustment company certain change stock utstande december base compensation plan begin grant performance grant share unit psus restrict stock unit rsus exercise addition stock option certain management level forfeit employee financial value individual stockbase utstande december incentive grant approach design grant equivalent prior approach mix stockbase exercise compensation award change psu rsu payout forfeit share company stock end year period subject term applicable award utstande december additionally psu payout contingent company weight average exercise price performance preset objective set objective include million option convert medco health option company grant million psus number option average price option weightedaverage grant date fair value exercisable december respectively company grant million rsus million option million option weightedaverage grant date fair million option respectively value respectively december million share forfeiture vesting significant period million share respectively available future grant connection medco health spinoff term company stockbase compensation plan number exercise price outstanding option summarize information stock option outstanding proportionately adjust maintain option holder exercisable december option thousand position spinoff result follow adjustment exercise outstanding exercisable price number average average number average range option life price option price nder weight average contractual life remain year weight average exercise price retiree similar benefit dependent pension postretirement benefit plan postretirement benefit plan company use december company define benefit pension plan cover measurement date substantially pension plan eligible employee united states certain postretirement benefit plan international subsidiary pension benefit unite connection company restructuring action state base formula consider final average pay note merck record termination charge year credit service addition company million million million provide medical dental life insurance benefit principally respectively pension plan million million eligible merck report shareholder million respectively postretirement cost health care life insurance benefit active benefit plan relate expand eligibility certain employee million million employee exit company million connection restructuring activity summarize information change plan asset company record curtailment loss million benefit obligation follow settlement loss million pension plan curtailment loss million million postretirement benefit plan postretirement pension benefit benefit respectively company change participant contribution air value plan asset service recognize eligibility postretirement january benefit plan amendment generate curtailment gain actual return plan million million asset addition company record settlement gain company contribution million settlement loss million benefit pay plan certain domestic pension plan result asset employee elect receive pension benefit lump sum payment air value plan asset company recognize federal subsidy december medicare prescription drug improvement modernization act act reduce benefit enefit obligation obligation certain postretirement benefit plan january million company recognize subsidy subsidy act accordance current accounting requirement service cost continue evaluate act regulation follow interest cost determine optimal approach incorporate impact actuarial loss gain act benefit pay net cost company pension plan consist plan amendment follow component curtailment termination benefit year end december ervice cost enefit obligation interest cost december expect return plan asset net amortization fair value pension plan asset include termination benefit precede table billion billion curtailment pension benefit obligation plan include table settlement billion billion pension cost reconciliation plan fund status net asset liability recognize december follow net pension cost attributable plan include table million million postretirement million pension benefit benefit net cost postretirement benefit pension consist follow component lan asset benefit obligation year end december unrecognized net loss ervice cost unrecognized plan interest cost change expect return plan asset asset liability net amortization ecognize curtailment asset termination benefit accrue postretirement benefit cost current liability defer income taxis noncurrent liability accumulate comprehensive loss merck report shareholder weight average asset allocation investment december accumulate benefit portfolio pension postretirement benefit plan obligation billion billion respectively december follow pension plan billion billion respectively pension plan company minimum pension liability million million december postretirement respectively represent extent pension benefit benefit accumulate benefit obligation exceed plan asset certain equity companys pension plan pension plan benefit obligation excess plan international equity asset december fair value plan fixedincome investment asset million billion respectively real estate benefit obligation billion billion respectively investment plan accumulate benefit obligation excess cash cash equivalent plan asset december fair value plan asset million million respectively accumulate benefit obligation million target investment portfolio company pension million respectively plan determined country base nature unrecognized net loss amount reflect experience differential liability consider demographic composition primarily relate difference expect actual plan participant average age year service active return plan asset effect change versus retiree status accordance local regulation actuarial assumption unrecognize net loss amount excess weight average target allocation certain threshold amortize net pension equities international equities fixedincome postretirement benefit cost average remain service investment real estate investment life employee amortization unrecognized net loss cash cash equivalent investment include company plan december expect insurance contract certain international pension plan increase net pension postretirement benefit cost target investment portfolio company approximately million annually postretirement benefit plan allocate company reassesse benefit plan assumption equities international equity regular basis weight average assumption fixedincome investment cash determine pension plan information follow investment portfolio asset allocation consistent longterm nature plan benefit obligation december diversify asset class portfolio cost invest iscount rate contribution pension plan postretirement expect rate return plan asset benefit plan expect million million respectively salary growth rate expect benefit payment follow enefit obligation iscount rate salary growth rate pension postretirement benefit benefit assumption determine pension plan postretirement benefit plan information follow december cost iscount rate expect rate return plan asset salary growth rate expect benefit payment base enefit obligation assumption measure benefit obligation include estimate future employee service expect receipt iscount rate subsidy act reflect salary growth rate expect postretirement benefit payment include postretirement benefit plan precede table follow million million million million million merck report shareholder expect rate return pension net primarily reflect million gain postretirement benefit plan represent average rate sale company percent equity stake return earn plan asset period benefit european joint venture johnson johnson include benefit obligation pay realize gain company investment portfolio net determined country basis develop expect rate primarily reflect million gain sale return country longterm historical return aggrastat product right united states realize gain datum consider actual return plan asset company investment portfolio relate favorable capital market experience reference interest rate environment information longterm return expectation asset interest pay million million category weight average expect return million countrys target portfolio develop accord allocation investment category expect taxis income portfolio performance reflect contribution active management appropriate company reconciliation company effective tax rate expect rate return remain unchanged statutory rate follow pension postretirement benefit plan tax rate health care cost trend rate assumption post retirement benefit plan follow statutory rate apply income continue december operation taxis ealth care cost trend rate assume differential arise year foreign earning rate cost trend rate assume tax exemption puerto decline rico operation year rate reach ultimate trend state taxis rate ajca percentage point change health care cost trend rate follow effect include tax effect minority interest contingency percentage point increase decrease reserve research credit export incentive miscellaneous ffect total service interest cost item component domestic company contribute approximately effect benefit obligation consolidated income continue operation taxis tax income continue operation consist income expense net year end december urrent provision year end december nter income federal foreign interest expense state exchange gain minority interest net eferre provision federal foreign minority interest include party share exchange state gain loss arise translation financial statement dollar reduce minority interest attributable redemption subsidiary variable rate prefer unit note merck report shareholder defer income taxis december consist taxis payable distribution earning practicable determine relate unrecognized deferred income lax liability addition asset liability asset liability company subsidiary operate puerto rico ther intangible singapore tax incentive grant expire inventory relate respectively accelerate company federal income tax return audit depreciation previously disclose internal revenue advance payment service irs substantially complete examination equity investment company tax return year pension opeb april connection examination irs issue compensation relate preliminary notice deficiency respect partnership vioxx legal defense transaction enter december cost reserve company receive final notice deficiency respect net operating loss transaction regard tax return specifically irs disallow certain royalty expense claim ubtotal deduction tax return preliminary notice valuation allowance propose disallow similar type expense tax otal defer taxis return company anticipate receive similar preliminary defer tax notice deficiency irs ultimately prevail liability position companys income tax ecognize increase approximately million plus interest approximately million penalty approximately prepay expense million year tax increase taxis approximately million plus interest approximately asset million irs likely similar claim year income taxis subsequent respect transaction potential payable disallowance later year compute similar basis defer income disallowance approximately tax million plus interest approximately million irs noncurrent propose penalty company respect period liability subject preliminary notice adjustment company net operating loss nol carryforward company anticipate irs seek impose penalty number jurisdiction significant period united kingdom nol carryforward million october irs issue summons expiration date valuation allowance current executive company connection establish certain canadian nol carryforward matter irs begin interview individual result legal entity reorganization december income taxis pay company vigorously disagree propose billion billion billion respectively stock adjustment intends aggressively contest matter option exercise significant impact taxis applicable irs judicial procedure appropriate pay stock option exercise reduce income taxis final resolution propose adjustment pay million million uncertain involve unsettled area law base respectively currently available information company provide previously disclose october ajca good estimate probable tax liability matter sign law ajca create temporary incentive resolution issue result tax liability multinational repatriate accumulate income earn significantly high low reserve establish outside united states december matter management currently believe resolution accordance ajca company repatriate material effect company financial position billion company record income liquidity unfavorable resolution tax charge million taxis income material effect company result operation cash relate repatriation million pay flow quarter adjustment record tax million pay quarter pay charge partially offset million january irs issue summon request benefit associate decision implement certain tax certain information connection minority interest equity planning strategy finance transaction enter merck intend company change intention indefinitely cooperate term summon reinvest accumulate earning earn subsequent december december foreign earning billion retain indefinitely subsidiary company reinvestment provision income merck report shareholder component accumulate comprehensive earning share income loss follows weight average common share computation basic earning common share december earning common share assume dilution share unrealized gain loss derivative million follow net unrealized gain investment minimum pension liability year end december cumulative translation adjustment relate verage common share equity investee outstanding common share issuable verage common share december million net unrealized gain outstanding assume dilution derivative associate option mature issuable primarily stockbase compensation plan month hedge anticipate foreign currency denominate sale period million million million common share issuable company segment report stockbase compensation plan exclude company operation principally manage computation earning common share assume dilution product basis merck pharmaceutical segment include effect antidilutive product market directly joint venture product consist therapeutic preventive agent sell comprehensive income prescription treatment human disorder merck sell component comprehensive income loss human health product primarily drug wholesaler follow retailer hospital government agency manage health care provider health maintenance organization institution pretax tax tax ear end december include nonreportable human animal health segment revenue profit segment unrealized gain derivative follow net loss realization erivative merck unrealize gain pharm aceutical total investment ear end december net loss realization nvestment egment revenue segment profit inimum pension liability include segment profit umulative translation adjustment equity income affiliate relate equity investee depreciation amortization ear end december ear end december unrealized loss derivative egment revenue net loss realization segment profit erivative nclude segment profit unrealize gain equity income affiliate investment depreciation amortization net income realization ear end december nvestment egment revenue inimum pension liability segment profit umulative translation adjustment include segment profit relate equity investee equity income affiliate depreciation amortization ear end december unrealize loss derivative net loss realization erivative unrealized gain investment net income realization nvestment inimum pension liability net applicable minority interestmerck report shareholder segment profit comprise segment revenue consolidate revenue geographic area derive certain element material production cost follow operating expense include component equity income loss affiliate depreciation amortization year end december expense internal management reporting present nited state chief operating decision maker company allocate europe middle east africa vast majority indirect production cost research japan development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix reconciliation total segment profit consolidated asset utilize division income continue operation taxis follows include segment profit reconciliation total segment revenue consolidate year end december sale follow egment profit profit year end december adjustment egment revenue unallocate revenue interest income interest expense equity income loss revenue primarily comprise miscellaneous affiliate corporate revenue sale relate divested product depreciation business supply sale amortization sale company product follow research development expense net year end december ocor fosamax profit primarily comprise miscellaneous cozaarhyzaar corporate profit operating profit relate divested singulair product business supply sale adjustment proscar represent elimination effect double counting certain primaxin item income expense equity income loss affiliate vasotecvaseretic include taxis pay joint venture level portion cosopttrusopt equity income report segment profit cancidas expense net include expense corporate maxalt manufacturing cost center miscellaneous income propecia expense net vioxx property plant equipment net geographic area vaccinesbiological locate follow december nite state present net discount return europe middle east africa primarily include sale human japan pharmaceuticals pharmaceutical animal health supply sale company joint venture revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion company disaggregate asset product billion billion service basis internal management report respectively information present merck report shareholder management report management responsibility financial statement include company file addition responsibility integrity objectivity company company submit new york stock financial statement rest management financial exchange nysf certificate ceo certify statement report management stewardship company aware violation company nyse corporate asset statement prepare conformity governance list standard generally accept accounting principle accordingly managements report lnternal control financial include amount base management well reporting estimate judgment nonfinancial information include annual report prepare management management responsible establish maintain consistent financial statement adequate internal control financial reporting term assure financial information reliable asset define exchange act rule management conduct safeguard management maintain effective system evaluation effectiveness internal control financial internal control procedure important element report base framework internal controlintegrate include careful selection training development framework issue committee sponsor operate financial manager organization organization treadway commission coso base provide appropriate division responsibility evaluation management conclude internal control communication aim assure company policy financial report effective december base procedure understand organization staff criterion internal controlintegrate framework issue internal auditor regularly monitor adequacy coso management assessment effectiveness application internal control worldwide basis internal control financial reporting december ensure personnel continue understand audit pricewaterhousecooper llp system internal control procedure policy independent register public accounting firm concern good prudent business practice pricewaterhousecooper llp issue report company periodically conduct management management assessment effectiveness stewardship program key management financial company internal control financial reporting personnel program reinforce importance include understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstande richard clark judy lewent commitment high ethical standard conduct chief executive officer executive vice president business president chief financial officer financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission audit committee report audit committee comprise independent director meet independent auditor judgment quality independent register public accounting firm acceptability company accounting principle clarity independent auditor management internal auditor disclosure degree aggressiveness assure carry respective conservatism accounting principle underlie responsibility audit committee discuss estimate audit committee review discuss receive letter independent auditor confirm audit financial statement management independence independent auditor internal recommend board director financial auditor access committee include regular statement include company file meeting management present security exchange commission audit committee meet independent auditor discuss fee scope result audit work peter cwendell rochelle lazarus include adequacy internal control quality chairperson thomas shenk financial reporting committee discuss wendell week merck report shareholder report independent register public accounting firm company management responsible maintain effective stockholder internal control financial reporting assessment board director merck inc effectiveness internal control financial reporting responsibility express opinion management complete integrate audits merck incs assessment effectiveness company internal consolidated financial statement control financial reporting base audit conduct internal control financial reporting december audit internal control financial reporting accordance audit consolidated financial standard public company accounting oversight statement accordance standard public board united states standard require plan company accounting oversight board united states perform audit obtain reasonable assurance opinion base audit present effective internal control financial reporting maintain consolidated financial statement material respect audit internal control financial opinion accompany consolidated balance sheet reporting include obtain understand internal control relate consolidated statement income retain financial reporting evaluate management assessment earning comprehensive income cash flow present testing evaluate design operating effectiveness fairly material respect financial position merck internal control perform procedure inc subsidiary december consider necessary circumstance believe december result operation audit provide reasonable basis opinion cash flow year period end company internal control financial reporting december conformity accounting principle process design provide reasonable assurance generally accept united states america reliability financial reporting preparation financial financial statement responsibility company statement external purpose accordance generally management responsibility express opinion accept accounting principle companys internal control financial statement base audits conduct financial reporting include policy procedure audits statement accordance pertain maintenance record reasonable standard public company accounting oversight board detail accurately fairly reflect transaction united states standard require plan disposition assets company provide reasonable perform audit obtain reasonable assurance assurance transaction record necessary permit financial statement free material preparation financial statement accordance generally misstatement audit financial statement includes accept accounting principle receipt examine test basis evidence support amount expenditure company accordance disclosure financial statement assess authorization management director company accounting principle significant estimate iii provide reasonable assurance prevention management evaluate overall financial statement timely detection unauthorized acquisition use disposition presentation believe audits provide reasonable company asset material effect basis opinion financial statement inherent limitation internal control internal control financial reporting financial reporting prevent detect misstatement opinion management assessment include projection evaluation effectiveness future period accompany management report internal control subject risk control inadequate financial reporting company maintain change condition degree effective internal control financial reporting compliance policy procedure deteriorate december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso fairly state material respect base florham park new jersey pricewaterhousecoopers llp criterion furthermore opinion company february maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso compensation benefit committee report compensation benefit committee comprise consistent longterm focus inherent company independent director approve compensation objective rdbase pharmaceutical business policy policy employee set compensation committee high proportion executive officer company executive officer committee seeks ensure compensation dependent longterm performance reward closely link company division team enhance stockholder value individual performance committee seeks ensure compensation benefit set level enable lawrence bossidy william bowen merck attract retain highly qualified employee chairperson johnnetta cole committee view stock ownership vehicle align william kelley interest employee companysstockholder merck report shareholder select financial datum merck inc subsidiarie million share amount esult year sale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income continue operation taxis tax income income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income cash dividend declare cash dividend pay common share capital expenditure depreciation earend position work capital property plant equipment net total asset longterm debt stockholder equity inancial ratio income continue operation sale net income average total asset earend statistic average common share outstanding million average common share outstanding assume dilution million number stockholder record number employee prior year amount reclassify reflect separate line item presentation restructuring cost amount include impact net tax charge primarily associate ajca repatriation restructuring action additional vioxx legal defense cost amount include impact withdrawal vioxx vioxx legal defense cost amount include impact implementation new distribution program wholesaler add result round decrease primarily reflect impact spinoff medco healthmerck report shareholder exhibit merck inc subsidiary follow list subsidiary company business state country state incorporation amrad pharmaceuticals pty ltd australia aton pharma inc delaware banyu pharmaceutical company ltd japan blue jay investments netherlands brc ltd bermuda charles frosst limit great britain chibret denmark chibret pharmazeutische gmbh germany chinamsd hivaids public private partnership inc china chippewa holdings llc delaware cloverleaf international holding luxembourg delaware llc delaware comsort inc delaware coophavet sas france coordinate patient care scandinavia norway crosswind netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holding panama frosst iberica spain frosst laboratories inc delaware frosst portuguesa produto farmaceuticos lda portugal hangzhou msd pharmaceutical company limited china hawk falcon llc delaware infodoc norway international indemnity ltd bermuda istituto richerche biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceutical company new jersey kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto viistotie finland laboratoire merck sharp dohmechibret snc france laboratorios abello spain laboratorios biopat spaincountry state incorporation laboratorio chibret spain laboratorios frosst spain laboratorios medichip spain laboratorios neurogard spain laboratorios quimicofarmaceutico chibret lda portugal maple leaf holding srl barbados mcm vaccine pennsylvania medco mexico manage care mexico medco holdings mexico medco servicios mexico mexico merck company incorporate delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck enterprises canada ltd canada merck finance inc delaware merck foreign sales corporation ltd bermuda merck frosst canada ltd canada merck frosst company canada merck frosst finco canada merck hamilton inc california merck holdings corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware merck oncology holdings inc delaware merck resource management inc delaware merck respiratory health company nevada merck inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprise netherlands merck sharp dohme europe inc delaware merck sharp dohme holding netherlands merck sharp dohme holding limit great britain merck sharp dohme corp delaware merck sharp dohme international limited bermuda merck sharp dohme investment netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealandcountry state incorporation merck sharp dohme panama panama merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden sweden merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme netherlands merck sharp dohme chibret switzerland merck sharp dohme comercializadora mexico merck sharp dohme doo croatia merck sharp dohme espana spain merck sharp dohme mexico mexico merck sharp dohme venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limit great britain merck sharp dohme gmbh austria merck sharp dohme holdings mexico mexico merck sharp dohme idea inc switzerland merck sharp dohme industria quimica veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international service netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland iceland merck sharp dohme llc russian federation merck sharp dohme limit great britain merck sharp dohme luxembourg holdings sarl luxembourg merck sharp dohme manufacturing ireland merck sharp dohme estonia merck sharp dohme pakistan limited pakistan merck sharp dohme peru srl peru merck sharp dohme quimica puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme mexico merck sharp dohme morocco merck sharp dohme sas france merck sharp dohme sia latvia merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology company inc nevada merck ventures inc delaware merial llp puerto rico merial thailand ltd thailand merial animal health ltd china merial animal health ltd great britain merial argentina argentina merial asia pte ltd singapore merial australia pty ltd australia merial netherlands merial belgium belgiumcountry state incorporation merial colombia colombia merial distribution sas france merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios spain merial limitedllc great britaindelaware merial nanjing animal health ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial uruguay merial sas france merial saude animal ltda brazil merial taiwan ltd taiwan merial venezuela venezuela holdings canada inc canada msd nippon holding netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd australia pty ltd australia msd australia superannuation pty ltd australia msd brazil investment netherlands msd chibropharm gmbh germany msd finance netherlands msd finance mexico llc delaware msd international holdings inc delaware msd ireland holdings luxembourg msd ireland investments ltd bermuda msd korea ltd korea msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd latin america services mexico msd limit great britain msd magyarorszg kft hungary msd mexico investment netherlands msd overseas manufacturing bermuda msd overseas manufacturing ireland ireland msd pharmaceuticals private limited india msd polska spzoo poland msd sharp dohme gmbh germany msd somerset ltd bermuda msd stamford singapore pte ltd singapore msd technology singapore pte ltd singaporecountry state incorporation msd technology delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd great britain msp distribution service llc nevada msp distribution service llc nevada msp marketing service llc nevada msp marketing service llc nevada msp singapore company llc delaware msp technology company llc delaware neopharme spa italy merck sharp dohme indonesia indonesia pasteur vaccin france readington investments inc new jersey rosetta inpharmatics llc delaware ruskin limited bermuda sanofi pasteur msd denmark sanofi pasteur msd switzerland sanofi pasteur msd gestion france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd great britain sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd spain sanofi pasteur msd spa italy sanofi pasteur msd snc france seneca llc delaware sharp dohme spain stellarx inc nevada suomen msd finland telerx marketing inc pennsylvania msd foundation limit great britain thomas morson son limited great britain tradewind manufacture srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany exhibit power attorney undersign appoint celia colbert kenneth frazier severally hisher true lawful attorney attorney execute behalf undersign behalf company officer director thereof attesting seal company annual report merck inc fiscal year end december securities exchange act include amendment thereto